Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
12/2011 | Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions December patent applications/inventions, industry category 12/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
12/29/2011 > 190 patent applications in 135 patent subcategories. patent applications/inventions, industry category

20110319315 - Muscle-building agent: A muscle-building agent comprising a whey protein hydrolyzate having a molecular weight distribution of 10 kDa or less, a main peak of 200 Da to 3 kDa, an average peptide length (APL) of 2 to 8, a free amino acid content of 20% or less, and antigenicity equal to or... Agent: Megmilk Snow Brand Co., Ltd.

20110319316 - Method for preventing and treating hyperpermeability: A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TX EX X E, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no TNF receptor binding activity and is cyclized, for the prevention and treatment of... Agent: Apeptico Forschung Und Entwicklung Gmbh

20110319317 - Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of Sirtuin 1 (SIRT1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC

20110319318 - Covalent milk protein/isothiocyanate complexes: The present invention relates to the field of complexes. Embodiments of the present invention relate to food-grade covalent complexes containing at least one milk protein and at least one ITC-compound and to the uses of such complexes, e.g., to reduce the perceived pungency of ITC-compounds, to produce antimicrobial effects and/or... Agent: Nestec S.a.

20110319319 - Antimicrobial kinocidin compositions and methods of use: The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γKC... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20110319320 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20110319321 - Mammalian colostrum derived nanopeptides for broadspectrum viral and recurrent infections with a method of isolation thereof: The present invention relates to nanopeptides isolated from mammalian colostrum with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors.... Agent:

20110319323 - Pharmaceutical composition and method of use to improve organ function: The present document describes a pharmaceutical composition as well as methods to improve organ function using a high dose of insulin and maintaining normal glycemia. Methods of intensive insulin therapy using the pharmaceutical composition are also described.... Agent:

20110319322 - Systems, methods and devices for achieving glycemic balance: Systems, methods and/or devices for optimizing a patient's insulin dosage regimen over time, comprising at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen, and data inputs corresponding at least to the patient's blood-glucose-level measurements determined... Agent: Hygieia, Inc.

20110319326 - Derivatives of benzothiazines, preparation thereof and application thereof as drugs: The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R1 represents a hydrogen or OR1 represents an ester or... Agent: Pierre Fabre Medicament

20110319324 - Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases: The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.... Agent: Five Prime Therapeutics, Inc.

20110319325 - Multi-component pharmaceuticals for treating diabetes: Activated fatty acids, pharmaceutical composition compositions including activated fatty acids, methods for using activated fatty acids to treat diabetes, and methods for preparing activated fatty acids are provided herein.... Agent: Complexa, Inc.

20110319327 - Polypeptides homologous to vegf and bmp1: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be... Agent: Genentech, Inc.

20110319328 - Bone morphogenetic protein compositions: The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal... Agent: Stryker Corporation

20110319329 - Use of somatostatin analogs in cluster headache: The present invention relates to the use of a Somatostatin (SRIF) analog which has a high binding affinity to human SSTR1,2,3,5, or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of cluster headache.... Agent: Novartis Ag

20110319330 - Methods for treating arthritis, autoimmune disease, and ischemia-reperfusion injury: The instant invention provides a method of treating an animal suffering a disease characterized by excessive apoptosis by administering a therapeutically effective amount of at least one serine protease inhibitor and thereafter monitoring a decrease in apoptosis. The inhibitor of the invention includes α1-antitrypsin or an α1-antitrypsin-like agent, including, but... Agent: Bio Holding, Inc.

20110319331 - Novel uses of fibrinogen: The invention relates to the use of fibrinogen for manufacturing a medicinal product for use in the prevention or treatment of severe acute haemorrhage, the medicinal product being intended for administration in an amount equal to at least 4.5 g of fibrinogen in a single dose.... Agent: Laboratoire Francais Du Fractionnement Et Des Biot

20110319332 - Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition: A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively.... Agent:

20110319333 - Method and compositions for the treatment and detection of endothelin-1 related kidney diseases: The present application relates to methods of treating HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 (ET-1) antagonists. The application further relates to a composition for the treatment of HIVAN and/or FSGS. A kit for detecting the presence of ET-1 or ET-1-associated biomarker in a biological sample is... Agent: Morehouse School Of Medicine

20110319334 - Compositions and methods for prevention and treatment of neurodegenerative diseases: Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions... Agent: Ramot At Tel-aviv University Ltd.

20110319335 - Combined administration of integrin receptor antagonists for anti-angiogenic therapy: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an αvβ3 antagonist with an α2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer.... Agent:

20110319337 - Dominant negative wnt2 compositions and methods of use: The present disclosure provides compositions, pharmaceutical preparations, kits and methods for inhibiting cell proliferation by contacting a cell expressing Fzd8 with a truncated Wnt2 polypeptide which acts as a dominant negative inhibitor of Fzd8 signaling. The present disclosure provides compositions, kits and methods for the detection of cancer by determining... Agent:

20110319336 - Selective anticancer chimeric peptide: It is an object of the present invention to provide a substance usable as an anticancer agent or DDS, which has intracellular stability, which is capable of evading side effects from functional disorder with respect to normal cells, or which has instantaneous effect. The inventors developed a novel chimeric peptide... Agent: Upstream Infinity, Inc.

20110319338 - Peptides that bind eukaryotic translation initiation factor 4e: Methods, compositions and kits for treating proliferative and non-proliferative diseases associated with abnormal protein synthesis. Chimeric peptide constructs are comprised in compositions and kits for use in the treatment of proliferative diseases, such as ovarian cancer, and for inhibiting protein synthesis in a tumor cell compared to a non-tumor cell.... Agent: The Board Of Regents Of The University Of Texas System

20110319339 - Neurotensin-derived branched peptides and uses thereof: t

20110319340 - Methods for treating cancer: The present invention includes methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a non-proteolytically activated thrombin receptor agonist.... Agent: The Board Of Regents, The University Of Texas System

20110319342 - Cell-specifically effective molecules on the basis of sirna and application kits for the production thereof and use thereof: A biologically inactivated cell-specifically effective molecule for biologically inactive transfection into a target cell to inhibit expression of genes in the target cell after biological activation of the molecule, by bonding to mRNA and with the formation of a RISC complex, the biologically inactivated cell-specifically effective molecule comprising siRNA coupled... Agent:

20110319341 - Method of controlling pests with biosurfactant penetrants as carriers for active agents: A penetrating composition can include an active agent that has an activity that is either beneficial for plants or controls pests. The composition can also include a penetrant that is present in an effective amount for carrying the at least one active agent into or through a medium, the medium... Agent:

20110319343 - Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders: The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as... Agent: Synergy Pharmaceuticals, Inc.

20110319345 - Combination therapy for treatment of cancer: The invention relates to compositions and methods for treating diseases. In particular aspects, the invention relates to administering a combination of a disintegrin with a microtubule stabilizing agent useful for treatment of cancer.... Agent: University Of Southern California

20110319346 - Electrostatic protein/glucosinolate complexes: The present invention relates to the field of electrostatic complexes. Embodiments of the present invention relate to food-grade electrostatic complexes containing at least one milk protein and at least one glucosinolate and to the uses of such complexes, e.g., to reduce the perceived bitterness of glucosinolates and/or to form and... Agent: Nestec S.a.

20110319344 - Flagellin related polypeptides and uses thereof: The use of flagellin and flagellin related polypectides for the protection of mammals from the effects of apoptsis is described.... Agent: Cleveland Clinic Foundation

20110319347 - Antioxidant agent: Disclosed is an antioxidant which can exhibit a higher antioxidant ability than known antioxidative peptides. The antioxidant according to the present invention comprises mimosine and/or a mimosine-containing peptide(s). The mimosine-containing peptide is a peptide which comprises at least one mimosine residue in its amino acid sequence. Mimosine has stronger antioxidant... Agent:

20110319348 - Brassinosteroids in treating prostatic hyperplasia and androgenic alopecia: Provided are formulations containing brassinosteroids or their derivatives for treating androgen-associated conditions, such as prostate problems. Particularly formulations comprising at least one brassinosteroid or a derivative thereof are provided for treating benign prostatic hyperplasia or androgenic alopecia.... Agent: Grasses Of Eden Ltd.

20110319349 - Methods for reducing platelet activation and for the treatment of thrombotic events: o

20110319352 - Compounds that bind oxysterol binding proteins, and methods of use thereof: The invention relates in part to the discovery that certain CRAMs, such as schweinfurthin A, target OSBPs (a family of oxysterol binding proteins). Because OSBPs have been shown to be integral to atherosclerosis and Alzheimer's disease (AD), one aspect of the invention relates to the use of CRAMs, or a... Agent: President And Fellows Of Harvard College

20110319350 - Glycoside compounds and pharmaceutical compositions thereof: The present invention provides glycoside compounds, methods of preparing such compounds, pharmaceutical compositions comprising such compounds, and a method for the treatment of hyperproliferative diseases using the same.... Agent: Centrose, LLC

20110319351 - Treating cancer with cardiac glycosides: The invention provides methods to treat cancer with cardiac glycosides.... Agent: University Of Louisville Research Foundation

20110319354 - Combination cancer therapy with an akt inhibitor and other anticancer agents: The invention relates to combination anticancer therapy with certain Akt inhibitor and other anticancer agents such as anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors.... Agent:

20110319353 - Treatment for spinal muscular atrophy: A method of treating spinal muscular atrophy. The method includes administering an effective amount of composition including a sodium-proton exchanger inhibitor and a pharmaceutically acceptable carrier or salt, to a subject with spinal muscular atrophy to ameliorate a symptom of spinal muscular atrophy.... Agent:

20110319355 - Methods for treating non-small cell lung cancer using 5-azacytidine: The present disclosure provides methods for treating subjects having non-small cell lung cancer, wherein the methods comprise administering to the subject a cytidine analog, such as 5-azacytidine. Also provided are methods relating to identification and treatment of particular non-small cell lung cancer types sensitive to particular cytidine analogs.... Agent:

20110319473 - Compositions and methods for enhancement of nucleic acid delivery: Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. In an embodiment, an article for delivering an active agent is included. The article can include a dehydrated... Agent: Surmodics, Inc.

20110319470 - Diagnosis, prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling: Provided herein is a method for gene expression profiling multiple myeloma patients into distinct subgroups via DNA hybridization and hierarchical clustering analysis of the hybridization data where the results may further be used to identify therapeutic gene targets. Also provided is a method for controlling bone loss in an individual... Agent:

20110319471 - Lna antagonists targeting the androgen receptor: The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of the androgen receptor expression is beneficial for the treatment of certain disorders, such as a hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising... Agent: Enzon Pharmaceuticals, Inc.

20110319472 - Methods of prognosticating and treating ewing sarcoma/pnet and other neoplasms: A method of distinguishing between Ewing sarcoma patients having a good prognosis relative to those having a poor prognosis by screening for specific genomic copy number alterations (CNA) isolated and/or measuring denticleless homolog (Drosophila) (DTL) protein levels from the tumors of patients diagnosed with Ewing Sarcoma.... Agent: Centro De Investigacion Del Cancer - Ibmcc (usal-csic)

20110319477 - Mutations of the pik3ca gene in human cancers: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority... Agent: The Johns Hopkins University

20110319474 - Sirna targeting cyclin-dependent kinase 4 (cdk4): Efficient sequence specific gene silencing for cyclin-dependent kinase 4 is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design... Agent: Dharmacon, Inc.

20110319469 - Snps of apolipoprotein b and modulation of their expression: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for diagnosis and treatment of diseases and conditions associated with expression of apolipoprotein B... Agent: Genzyme Corporation

20110319475 - Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Brain derived neurotrophic factor (BDNF), in particular, by targeting natural antisense polynucleotides of Brain derived neurotrophic factor (BDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases... Agent: Opko Curna, LLC

20110319476 - Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Glial cell derived neurotrophic factor (GDNF), in particular, by targeting natural antisense polynucleotides of Glial cell derived neurotrophic factor (GDNF). The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent: Opko Curna, LLC

20110319478 - Compositions to treat cardiac pacing conditions: The HCN polynucleotide includes a nucleotide sequence encoding an HCN polypeptide having channel activity. The amino acid sequence of the HCN polypeptide and the amino acid sequence of a reference polypeptide have at least 80% identity, where the reference polypeptide begins with an amino acid selected from amino acids 92-214... Agent: Medtronic, Inc.

20110319480 - Method of inducing and/or enhancing an immune response to tumor antigens: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen. nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid or vaccines comprising the aforementioned to a lymphatic site.... Agent:

20110319479 - Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1 alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.... Agent: Vascular Biogenics Ltd.

20110319356 - Methods of treating optic disorders: The present invention relates to methods for treating optic disorders or for reducing or alleviating the signs, symptoms, or pathological conditions related to such optic disorders. In particular, methods are provided for treating optic disorders, or reducing the symptoms thereof, the methods involving the administration of one or more downstream... Agent:

20110319357 - Hyaluronic acid derivatives: The present invention relates to the modification of hyaluronic acid (HA) with aryl/alkyl succinic anhydrides (ASA) to produce aryl/alkyl succinic anhydride HA derivatives, to the derivatives as such, and to their applications and uses, particularly in the cosmetic and biomedical industries. The ASA-HA derivatives are expected to have interesting properties... Agent: Novozymes Biopolymer A/s

20110319358 - Glucosamine and method of making glucosamine from microbial biomass: Glucosamine suitable for human or animal consumption is disclosed. The glucosamine is derived from fungal biomass containing chitin. Various methods of producing glucosamine by acid hydrolysis of fermented fungal biomass are also disclosed.... Agent: Cargill, Incorporated

20110319359 - Indanyl compounds: Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof:... Agent: Daiichi Sankyo Company, Limited

20110319361 - Boron-containing small molecules: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part... Agent: Anacor Pharmaceuticals, Inc.

20110319360 - Method of including apoptosis/cell death in leukemia cell using a purine nucleoside analogue: A method of inducing apoptosis or cell death in a leukemia cell includes subjecting the cell to a purine nucleotide analogue, LMP-420 (2-amino-6-chloro-9-[5(dihydroxyboryl)-pentyl] purine).... Agent: U.s. Department Of Veterans Affairs

20110319362 - Stat3 ligands and therapeutic uses thereof: Inhibitors of STAT3 are disclosed. Methods of using the STAT3 inhibitors in the treatment of diseases and conditions wherein inhibition of STAT3 provides a benefit, like cancers, also are disclosed.... Agent:

20110319363 - Novel phosphonic acid compounds as inhibitors of serine proteases: The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders.... Agent:

20110319364 - Foaming alcohol compositions with selected dimethicone surfactants: Foaming alcohol compositions with selected dimethicone surfactants are disclosed. The dimethicone surfactants are PEG-8 to PEG-12 linear dimethicone surfactants and in particular PEG-10 linear dimethicone surfactant. The compositions are useful as antimicrobial products and in particular handcare or skincare products.... Agent: Ecolab Usa Inc

20110319365 - Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents: wherein A represents an ammonium species selected from the conjugate acid of a basic amino acid, quaternary ammonium, aliphatic ammonium, heterocyclic ammonium, aromatic ammonium, substituted and unsubstituted pyridinium, guanidinium, and amidinium, and wherein X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and... Agent:

20110319366 - Plasma carboxypeptidase b inhibitors: e

20110319367 - Phenazopyridine compounds: The present invention is directed to substituted phenazopyridines represented by Formula I. The present invention also relates to the discovery that compounds of Formula I have increased bioavailability as compared to unconjugated phenazopyridine.... Agent: Pinnacle Pharmaceuticals, Inc.

20110319368 - Once daily formulations of tetracyclines: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.... Agent: Supernus Pharmaceuticals, Inc.

20110319370 - Combination hormone therapy for the eye: An ophthalmic instillation composition which contains melatonin and at least one other hormone, typically an estrogen but also possibly testosterone or another aromatasable androgen. The instillation is designed to reduce or eliminate cataracts in men or women to which such an ophthalmic instillation composition is administered.... Agent: Duquesne University Of The

20110319369 - Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent: The invention describes methods of treating cancer in which a therapeutically-effective amount of a 17α-hydroxylase/C17,20-lyase inhibitor is administered to a subject in need thereof, including a subject with a refractory cancer and/or a subject currently undergoing another cancer treatment, wherein the 17α-hydroxylase/C17,20-lyase inhibitor is administered in combination with a therapeutically-effective... Agent: Tokai Pharmaceuticals, Inc.

20110319371 - Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol: Novel pharmaceutical formulations of a beta-2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.... Agent: Glaxo Group Limited

20110319372 - Method of diagnosing and therapeutically treating a patient for a traumatic brain injury: Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the... Agent: Scott & White Healthcare

20110319373 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Otonomy, Inc.

20110319374 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Otonomy, Inc.

20110319375 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Otonomy, Inc.

20110319376 - Methods and apparatus for transdermal or transmucosal application of testosterone: Methods, formulations, and devices for providing transdermal or transmucosal delivery of testosterone to female subjects in need thereof. The formulations and methods treat symptoms of hormonal disorders including hypogonadism, female sexual desire disorder, female menopausal disorder, and adrenal insufficiency.... Agent: Antares Pharma Ipl Ag

20110319377 - Controlled release corticosteroid compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and... Agent: Otonomy, Inc.

20110319379 - Substituted indazole amides and their use as glucokinase activators: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R4, R6, X, Y and Z are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and the pharmaceutical compositions... Agent:

20110319378 - Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer: e

20110319380 - Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth... Agent: Sunovion Pharmaceuticals Inc.

20110319381 - Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof: The invention relates to a compound of the general formula (I) in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy, NR8R9 group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond... Agent: Sanofi

20110319382 - Compositions comprising a calcium channel blocker or a calmodulin blocker for use in the removal of hyperplastic skin lesions: A composition, use of and a method of removing a hyperplastic skin lesion on a mammal comprising administering to the lesion or locus thereof a therapeutically effective amount of a composition comprising a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker... Agent:

20110319383 - Extended release formulations comprising quetiapine and methods for their manufacture: The present invention relates to extended release formulations of quetiapine and its pharmaceutically acceptable salts. The formulations comprise polymers, preferably hydroxypropyl methylcellulose of different viscosities, selected to cause the formulations to conform to preselected quetiapine release profiles. A process for the manufacture of said formulations is also disclosed.... Agent: Astrazeneca Ab

20110319384 - Pharmaceutical compositions: The present invention provides methods of treatment with a pharmaceutical composition, more particularly a sustained release pharmaceutical composition, comprising 11-[4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo-[b,f][1,4]thiazepine or a pharmaceutically acceptable salt thereof, as well as new and improved methods for treating a variety of psychological disorders and conditions including, but not limited to, Mood Disorders and... Agent: Astrazeneca Ab

20110319385 - Quinoxaline compound: The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a... Agent: Astellas Pharma Inc.

20110319387 - Indole derivatives for treating neurodegenerative diseases: or to a pharmaceutically acceptable salt thereof or to a stereoisomer or mixture of stereoisomers at any proportions, where: X1 is a CH2 or C═O group; X2 is a linear saturated or unsaturated carbohydrate chain with 8 to 24 carbon atoms; R1 is a hydrogen atom or an OH or... Agent: Centre National De La Recherche Scientifique (cnrs)

20110319386 - Neurogenesis by muscarinic receptor modulation: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent... Agent: Braincells Inc.

20110319389 - Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.... Agent: Tonix Pharmaceuticals, Inc.

20110319388 - Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure... Agent:

20110319390 - 6-aminoisoquinoline compounds: 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and... Agent: Aerie Pharmaceuticals, Inc.

20110319393 - Anthelmintic agents and their use: This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceutical compositions and kits comprising the compounds and salts, uses of the compounds... Agent:

20110319391 - Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease,... Agent:

20110319392 - Thiazole sulfonamide and oxazole sulfonamide kinase inhibitors: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent:

20110319394 - Fused heterocyclic compounds: e

20110319395 - Pharmaceutical formulation of olanzapine: A pharmaceutical formulation comprising a homogeneous mixture of (a) olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a monosaccharide and/or oligosaccharide, (c) a polysaccharide and, optionally, further ingredients.... Agent: Krka, Tovarna Zdravil, D.d.

20110319396 - Benzodiazepin-2-on derivatives: The present invention relates to a compound represented by the formula (I): wherein R1 represents a hydrogen atom or the like; R2 represents lower alkyl or the like; R3 and R4 represent lower alkyl or the like; R5 represents phenyl or the like; R6 represents a hydrogen atom or the... Agent: Msd K.k.

20110319397 - Novel n-oxides of furanyl-oxadiazolyl-diazabicyclononane derivatives and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Neurosearch A/s

20110319398 - Inhibition of yops translocation: The disclosure relates to compounds and methods of inhibiting type three secretion system effector molecules, to methods of detecting compounds that inhibit Yops translocation, and to methods of treating or preventing infections by administering compounds described herein to a subject in need thereof.... Agent: Tufts University

20110319399 - External preparation containing analgesic/anti-inflammatory agent: e

20110319400 - Prokineticin 1 receptor antagonists for the treatment of pain:

20110319401 - Five crystal forms, methods of preparation, pharmaceutical compositions and applications of xlf-iii-43: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals... Agent: Institute Of Mataria Medica, Chinese Academy Of Medical Sciences

20110319402 - Aerosol formulation for the inhalation of beta agonists: The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula (1) wherein the groups R1, R2, R3 and X″ may have the meanings given in the claims and in the description, for inhalation.... Agent: Boehringer Ingelheim International Gmbh

20110319403 - Bicyclic compounds as inhibitors of diacylglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent: Schering Corporation

20110319404 - Method for treating non-hodkin's lymphoma: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating non-Hodgkin's lymphoma, in a subject in need thereof.... Agent: Synta Pharmaceuticals Corp.

20110319405 - Treatment and prevention of diffuse parenchymal lung disease by selective active-site mtor inhibitors: Embodiments are related to new uses for selective active-site mTOR inhibitors in treating or preventing pulmonary fibrosis in diffuse parenchymal lung disease (DPLD) patients, such as a DPLD of environmental cause, a collagen vascular disease (e.g., scleroderma and rheumatoid arthritis), an idiopathic interstitial pneumonia (e.g., idiopathic pulmonary fibrosis and nonspecific... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110319406 - 2-pyridyl substituted imidazoles as therapeutic alk5 and/or alk4 inhibitors: This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.... Agent: Ewha University-industry Collaboration Foundation

20110319407 - Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and use thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which... Agent:

20110319408 - Methods of treating fibrosis, cancer and vascular injuries: This invention relates to use of inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4) in treating, preventing, or reducing fibrosis, cancer, and vascular injuries.... Agent: Ewha University-industry Collaboration Foundation

20110319409 - 7-aza-quinazoline pde10 inhibitors: i

20110319410 - Pyrazine derivatives and use as pi3k inhibitors: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Merck Serono Sa

20110319411 - Isoindolinone and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtis Pharmaceuticals, Inc.

20110319412 - Piperidine and pyrrolidine derivatives having npy y5 receptor antagonism: A is substituted or unsubstituted monocyclic aryl or monocyclic heterocyclyl; X is a single bond or C(═O); Y is a single bond, CR5R6NR7 or C(═O)NR7; R1 and R2 are independently hydrogen or substituted or unsubstituted alkyl; R3 is substituted or unsubstituted aryl or heterocyclyl; R4 is halogen, substituted or unsubstituted... Agent: Shionogi & Co., Ltd.

20110319413 - Piperazine compound capable of inhibiting prostaglandin d synthase: i

20110319414 - Novel triazine derivative and pharmaceutical composition comprising the same:

20110319415 - Susceptibility to hsp90-inhibitors: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the... Agent: Max-planck-gesellschaft Zur F+e,uml O+ee Rderung Der Wissens

20110319416 - Subunit selective nmda receptor antagonists for the treatment of neurological conditions: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-E, and pharmaceutically acceptable salts, esters, prodrugs or... Agent: Emory University

20110319417 - Methods and compositions for treating anxiety: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.... Agent:

20110319418 - Prokineticin 1 receptor antagonists for the treatment of pain: t

20110319419 - Methotrexate adjuvants to reduce toxicity and methods for using the same: Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine... Agent:

20110319420 - Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containing compounds thereof and use as protein kinases inhibitor: The invention provides a new kind of dihydroindene amide compounds of general formula I or their pharmaceutically acceptable salts or prodrug thereof which can be used as protein kinase inhibitor. The invention provides a preparation method of the kind of compounds, the pharmaceutical compositions containing the compounds, the method for... Agent: Harbin Gloria Pharmaceuticals Co., Ltd

20110319421 - Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor: The invention relates to compounds of the formula R1 is selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorinated linear C1-C3 alkyl; R2 is hydrogen or methyl; R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy, R4 is C1-C2-alkyl... Agent: Abbott Gmbh & Co., Kg

20110319422 - Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is... Agent: Alkermes, Inc.

20110319423 - Novel dopamine d3 receptor ligands and preparation and medical uses of the same: The present invention relates to a novel piperazine derivative represented by Formula I having an activity for regulating dopamine D3 receptor, stereoisomers thereof, pharmaceutically acceptable salts or solvates, and a pharmaceutical composition comprising the compound, a process for preparing the same, and use thereof in the prevention or treatment of... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Science, P.l.a

20110319425 - Heterotricyclic compounds as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to novel compounds of Formula (I), wherein X1, X2, Y, Z1, Z2, Z3, M and (A)m are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR4”) which are useful for the treatment or prevention of central nervous system disorders as... Agent:

20110319424 - Naphthyridin-2(1h) -one compounds useful as antibacterials: wherein substituents R1, R2 and R5 are as defined, and Ar represents substituted phenyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, furanyl, imidazolyl and thiophenyl; compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds,... Agent:

20110319426 - Substituted isoindoles: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage,... Agent: Astrazeneca Ab

20110319427 - Use of 5ahq and bortezomib for the treatment of hematological diseases: The disclosure provides methods and compositions for treating hematological malignancies. In particular, the disclosure provides methods and compositions for treating leukemia, lymphoma and multiple myeloma using bortezomit and 5AHQ (5-ammo-8-hydroxyqumolme) and related compounds that bind non-competitively to an alpha unit of 2OS proteasome and inhibit proteasome activity Kits and commercial... Agent: University Health Network

20110319431 - Bis aromatic compounds for use as ltc4 synthase inhibitors: wherein Y, ring A, D1, D2a, D2b, D3, L1, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a... Agent: Biolipox Ab

20110319430 - Fungicidal pyrazoles: e

20110319429 - Substituted 1,1,3,1-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction: Compounds useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) and methods of using the compounds.... Agent:

20110319428 - Thiazole derivatives as pesticides: The present application relates to novel heterocyclic compounds, to their use for controlling animal pests including arthropods and in particular insects, and to processes for preparing the novel compounds.... Agent: Bayer Cropscience Ag

20110319432 - Fungicidal compositions comprising fluopyram and 5-ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine: Fungicidal compositions comprising as active components Fluopyram and 5-Ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine in a synergistically effective amount, methods for controlling phytopathogenic harmful fungi using mixtures of Fluopyram and 5-Ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine, the use of Fluopyram and 5-Ethyl-6-octyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-ylamine for preparing such mixtures, and also compositions and seed comprising such mixtures.... Agent: Basf Se

20110319433 - Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation: Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.... Agent: Chemocentryx, Inc.

20110319434 - Bicyclic heterocyclic derivatives and methods of use thereof: The present invention relates to novel Bicyclic Heterocyclic Derivatives, pharmaceutical compositions comprising the Bicyclic Heterocyclic Derivatives and the use of these compounds for treating or preventing treating allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a cognitive disorder, a metabolic... Agent: Schering Plough Corporation

20110319435 - Fungicide mixtures: The invention relates to a method for combating fungi and spores and suitable means therefor, and to the use thereof.... Agent: Lanxess Distribution Gmbh

20110319436 - Methods and compositions for modulating ire1, src, and abl activity: Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for treating diseases caused by the activity or inactivity of Ire1, Src, or Abl.... Agent: The Regents Of The University Of California

20110319439 - Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists: s

20110319437 - Iminopropene compound and use thereof: The compound (I) or a salt thereof has an excellent controlling activity against pests. Then the compound (I) or a salt thereof is useful for an active ingredient of a pesticidal composition.... Agent: Sumitomo Chemical Company, Limited

20110319438 - Novel sulfonamides as l-cpt1 inhibitors: e

20110319440 - Process for preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds:

20110319441 - Manufacture of variable density dosage forms utilizing radiofrequency energy: The present invention features the present invention features a tablet including at least one pharmaceutically active ingredient, wherein the shape of said tablet includes at least one major face wherein: (i) the peak penetration resistance at the perimeter of said major face of the tablet is at least about 10%... Agent:

20110319442 - Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration: The present invention relates in general to the field of modulators of the innate immune system, particularly to pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof, preferably suitable for local administration, such as, intravesical administration. In addition, the present invention concerns the use of imidazoquinolin(amines) and derivatives thereof for intravesical treatment... Agent: Telormedix Sa

20110319443 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent:

20110319444 - Quinuclidine carbonate salts and medicinal composition thereof: Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.... Agent: Chiesi Farmaceutici S.p.a.

20110319445 - Heteroaryl antagonists of prostaglandin d2 receptors: Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent... Agent: Amira Pharmaceuticals, Inc.

20110319446 - Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses: s

20110319447 - Triazole compounds that modulate hsp90 activity: The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising... Agent: Synta Pharmaceuticals Corp.

20110319448 - Guanidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for... Agent: Theravance, Inc.

20110319449 - Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists:

20110319450 - Benzimidazole compound crystal: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.... Agent: Takeda Pharmaceutical Company Limited

20110319451 - 5-ht6 receptor and modulators thereof for the treatment of insulin-related disorders: The present invention relates to a method for identifying a glycemic stabilizing compound, by: a) contacting a candidate compound with a 5-HT6 receptor, b) determining whether 5-HT6 receptor functionality is increased, and c) determining whether a glycemic marker is directly modulated, where an increase in 5-HT6 receptor functionality and direct... Agent:

20110319452 - Cyano anthranilamide insecticides: Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide thereof or a suitable salt of the compound (e.g., as a composition described herein). This invention also pertains to a... Agent: E.i. Du Pont De Nemours And Company

20110319453 - Methods of administering pirfenidone therapy: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.... Agent: Intermune, Inc.

20110319454 - Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity: The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders.... Agent: Allergan, Inc.

20110319455 - Antifungal treatment: A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is... Agent:

20110319456 - Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same: Novel benzoarylureido compounds and a use thereof for prevention and/or treatment of the neurodegenerative brain disease are provided. The neurodegenerative brain diseases may include Alzheimer's disease, dementia, Parkinson's disease, stroke, amyloidosis, Pick's disease, Lou Gehrig's disease, Huntington's disease, Creutzfeld-Jakob disease, and the like.... Agent: Korea Institute Of Science And Technology

20110319457 - Deferacirox dispersible tablets: The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.... Agent: Novartis Ag

20110319458 - Compound with agitation effect on peroxisome proliferator-activated receptor. process for its preparation and use thereof: The present invention provides a novel compound of formula I, which has an agitation effect on the peroxisome proliferator-activated receptor subtype δ (PPARδ), to a pharmaceutical composition comprising the compound, to a process for preparation of the compound and to use of the compound in the manufacture of a medicament... Agent: Zhejiang Hisun Pharmaceutical Co., Ltd.

20110319459 - Compounds and methods for treating cancer and diseases of the central nervous system: compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells.... Agent: Queens University At Kingston

20110319460 - Kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.... Agent: Allergan, Inc.

20110319461 - Novel salts, polymorphs, and synthetic processes regarding imidazole derivative: The present invention relates to a process for producing 2-[1-(S)-carboxy-2(S)-[3-(3,5-dichloro-benzyl)-3H-imidazol-4-yl]-ethylamino]-4-methyl-pentanoic acid, as well as novel salts, including hydrates and solvates thereof, and novel crystalline and amorphous forms thereof.... Agent: Ore Pharmaceuticals Inc.

20110319462 - Use of dithiine-tetracarboximides for controlling phytopathogenic fungi: The present invention relates to the use of novel and of known dithiine-tetracarboximides for controlling phytopathogenic fungi, and to methods of controlling phytopathogenic fungi in plant protection, and to plant protection compositions comprising these dithiine-tetracarboximides.... Agent: Bayer Cropscience Ag

20110319463 - Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients: e

20110319464 - Methods for treating benign prostatic hyperplasia: Patients having symptoms associated with benign prostatic hyperplasia can be treated with a once daily composition containing silodosin or a pharmaceutically acceptable salt thereof.... Agent: Kissei Pharmaceutical Co., Ltd.

20110319465 - Estrogen receptor modulators and uses thereof: A method for preventing, diagnosing, or treating a condition mediated by an estrogen receptor by administering to a patient in need thereof an effective amount of a compound of formula I, II, or a combination thereof: wherein R1, R3, R4, and R5 are independently selected from H, OH, and ORa;... Agent: University Of Medicine And Dentistry Of New Jersey

20110319467 - Absorption enhancement of statins and omega fatty acids: A composition and method to enhance absorption and bioavailability of Statin and Omega fatty acids consumed by humans and in an anhydrous base is presented.... Agent:

20110319466 - Method and composition for treating heart failure: A method and composition for treating, preventing or ameliorating heart failure, cardiac hypertrophy, and/or myocardial dysfunction includes administering a therapeutically effective amount of a HDAC inhibitor, such as phenylbutyrate, in combination with an ACE inhibitor, such as captopril.... Agent: U.s. Department Of Veterans Affairs

20110319468 - Cyclic amine compounds: Compounds exhibiting calcium receptor antagonist activity that are safe and orally administrable having Formula (I) or pharmaceutically acceptable salts thereof... Agent: Daiichi Sankyo Company, Limited

20110319481 - Schweinfurthin analogues: Methods and intermediates for preparing enantiomerically enriched Schweinfurthin analogs which are useful for the treatment of cancer, as well as novel Schweinfurthin analogs having anti-cancer activity, compositions comprising such analogs and therapeutic methods comprising administering such analogs.... Agent: University Of Iowa Research Foundation

20110319483 - 1-adamantyl chalcones for the treatment of proliferative disorders: t

20110319482 - Novel treatments: The present invention relates to the treatment of the premonitory symptoms of migraine, to the treatment of aura associated with or without migraine, epilepsy, non-epileptic seizures, stroke or other cardiovascular disorders, to the pre-emptive treatment of aura, migraine, epilepsy, stroke or other cardiovascular disorders, to the treatment of migraine recurrence... Agent:

20110319484 - Neuroprotective compounds: The invention describes the use of (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl-1-naphthalenyl propanoate derivatives, optionally mono- or di-methylated at the carbon in the alpha position of propanoic acid, of formula (I), where R is CH3CH2CO—, (CH3)2CHCO— or (CH3)3CCO—, its hydroxy acid forms and the pharmaceutically acceptable salts of said hydroxy acids, as neuroprotective compounds potentially... Agent: Parque Tecnologico De Ciencias De La Salud

20110319485 - Composition having anti-helicobacter pylori activity and its application to inhibit helicobacter pylori: The present invention provides a composition having anti-Helicobacter pylori activity and the composition contains ovatodiolide with effective dosage to inhibit Helicobacter pylori growth or ovatodiolide related substances and its acceptable carrier. The present invention also provides a method for treating ovatodiolide to produce a composition for killing Helicobacter pylori. The... Agent: Yushen Biotechnology & Medical Co, Ltd.

20110319486 - Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves... Agent:

20110319488 - Anionic oil-in-water emulsions containing prostaglandins and uses thereof: A colloidal anionic oil-in-water emulsion includes a prostaglandin, an oil having a iodine value ≦2, a surfactant and water, provided the anionic oil-in-water emulsion does not contain polyvinyl alcohol. The use of the anionic oil-in-water emulsions for enhancing the stability of the prostaglandins, for the treatment of ocular hypertension and/or... Agent: Novagali Pharma Sa

20110319487 - Polymeric delivery system for a nonviscous prostaglandin-based solution without preservatives: c

20110319489 - Enhanced stability peracid compositions: The present invention is directed to stabilized peracid compositions. Stabilizing compositions including a metal salt and a chelating agent are added to compositions including peracids. The results stabilized peracid compositions have increased shelf life and storage stability.... Agent: Ecolab Usa Inc.

20110319490 - Methods and compositions for the treatment of irritable bowel syndrome: A method for a prevention and/or treatment of irritable bowel syndrome or amelioration of a symptom thereof in a subject, comprises administering to said subject an effective amount of a compound of formula I:... Agent: Medicinova, Inc.

20110319491 - Anhydrous depigmenting compositions comprising, within the fatty phase thereof, a solubilized phenolic compound and a retinoid: Novel anhydrous dermatological depigmenting compositions, especially for topical application, contain, within the fatty phase thereof, as pharmaceutical active agents, a dissolved phenolic compound and a retinoid.... Agent: Galderma Research & Development

20110319492 - Manufacture of tablets from energy-applied powder blend: The present invention features a process for making tablets containing one or more pharmaceutically active agent(s) and one or more binder(s), the method including the steps of (i) applying energy to a powder blend comprising the pharmaceutically active agent(s) and the binder(s) for a sufficient period of time to activate... Agent:

20110319493 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: President And Fellows Of Harvard College

20110319494 - Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase... Agent: Neurim Pharmaceuticals (1991) Ltd.

20110319495 - Pharmaceutical composition for hepatitis treatment and applications: A pharmaceutical composition for hepatitis treatment, which comprises lucidone as an active ingredient; and a pharmaceutical acceptable carrier. As lucidone is a natural cyclopentenedione, the pharmaceutical composition of present invention has lesser side effects. The present invention is also related to the application of the pharmaceutical composition.... Agent:

20110319496 - Process for the preparation of ajoene: A process for the preparation of ajoene, and of ajoene having a relatively high purity which may be obtained by the process. This invention also relates to processes for the preparation of allicin, and to a process for freeze concentrating allicin.... Agent: Neem Biotech Limited

20110319497 - Ampk activator: A method for suppressing fatty liver in a subject in need thereof by administering to the subject an effective amount of resveratrol.... Agent: Kao Corporation

20110319498 - Transparent goniochromatic multilayer effect pigment: A multilayer effect pigment includes a transparent substrate, a layer of high refractive index material on the substrate, and alternating layers of low refractive index and high refractive index materials on the first layer, the total number of layers being an odd number of at least three, all adjacent layers... Agent: Basf Corporation

20110319499 - Methods for the detection of advanced glycation endproducts and markers for disease: The present invention provides compositions and methods for detecting carboxymethyl-lysine (CML) and circulating receptor for advanced glycation end (RAGE) products, and methods for correlating CML and RAGE levels with age-related disease, hi particular, serum CML and/or circulating receptor for advanced glycation end (RAGE) products can be used as a clinical... Agent: The Johns Hopkins University

20110319501 - Agricultural composition: Additives for compost for ornamental plants and/or agricultural production plants in the form of granules comprising a) between 5 and 65% by weight on the total weight of the composition of a superabsorbent polymer, for agriculture (SAP), b) between 35 and 70% by weight on the total weight of the... Agent:

20110319500 - Alkali swellable acrylic emulsions without surfactants, use thereof in aqueous formulations, and formulations containing them: The present invention pertains to new alkali swellable thickening emulsions, free of surfactants and solvents other than water: as a result, all drawbacks related to the use of solvents, or to the formation of foam in the case of surfactants, are avoided. These new emulsions contain a certain quantity of... Agent: Coatex S.a.s.

20110319502 - Compositions and methods for enhancing reduction of spore-forming microorganisms: A pharmaceutical formulation comprises a pharmaceutically acceptable preservative and a material selected from the group consisting of D-glucose, sucrose, maltose, D-mannose, trehalose, glutamic acid, mixtures thereof, and combinations thereof, wherein the formulation has enhanced preservative efficacy against spore-forming microorganisms. The formulation can further comprise boric acid and/or phosphate. A method... Agent:

20110319503 - Soft capsule based on starch and a method and device for the production thereof: A method for producing starch soft capsules comprises the following steps: preparing a mixture comprising starch, plasticizer and water, wherein more than 50 weight percent of the starch is present in the form of particles of granular starch; shaping the mixture to form a film in a shaping process; solidifying... Agent:

20110319504 - Method for the manufacture of oligo- and polyesters from a mixture of carboxylic acid obtained from suberin and/or cutin and use thereof: The invention relates to a method for processing mixtures of carboxylic acids obtained as hydrolysis products of suberin and cutin, particularly suberin and cutin isolated from birch bark, to give mono-, oligo- and polyesters, or corresponding ester-ethers, as well as the use of the products thus obtained as lubricants, fuel... Agent: Valtion Teknillinen Tutkimuskeskus

  
12/22/2011 > 187 patent applications in 132 patent subcategories. patent applications/inventions, industry category

20110312872 - Norrin in the treatment of diseases associated with an increased tgf-beta activity: The present invention relates to Norrin or a functional fragment thereof in the treatment or prevention of diseases associated with an increased TGF-beta activity. In particular, the use of said Norrin or functional fragment thereof to treat fibrotic diseases/disorders or proliferative disorders, like cancers, is part of this invention.... Agent: Universit&#xc4 T Regensburg

20110312873 - N-terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic: The invention refers to multibasic, N-terminally modified tetrapeptide mimetics with a C-terminal P1-arginine mimetic, methods for their production and use for therapy and prophylaxis of diseases, caused by bacterial pathogens or viruses, as well as for therapy and prophylaxis of diabetes, arteriosclerosis, cancer, Alzheimer's or the onset of obesity, as... Agent: Philipps-universitat Marburg

20110312874 - Use of a trpc channel for the treatment of a cardiovascular disease: The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of screening a modulator of the... Agent: Sanofi

20110312875 - Peptidic compounds: The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are... Agent: University Of Wollongong

20110312876 - Method of determining types i, ii, iii, iv or v or methicillin-resistant staphylococcus aureus (mrsa) in a biological sample: Disclosed are diagnostic methods for determining a subtype of methicillin-resistant Staphylococcus aureus (MRSA) in a biological sample of a mammal. Methods include providing a biological sample of the mammal, performing a PCR analysis of the biological sample, and analyzing the PCR amplicons with respect to their sizes so as to... Agent: Medical Diagnostic Laboratories, LLC

20110312877 - Engineered tunable nanoparticles for delivery of therapeutics, diagnostics, and experimental compounds and related compositions for therapeutic use: Biomedical nanoparticles are disclosed based on new engineered modular carrier macromolecules, on engineered macromolecules or associated entities providing an internal nanoparticle structure, and compositions for minimizing non-specific binding of the nanoparticles while enabling efficient and convenient targeting to cells and tissues. These nanoparticles may be used to deliver atomic or... Agent: Aparna Biosceiences

20110312878 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X.... Agent: Zealand Pharma A/s

20110312879 - Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity: Template-fixed peptidomimetics formula (Ia) formula (Ib) wherein Z is a template-fixed chain of 14 α-amino and/or α-hydroxy acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Pro, Gly, a glycolic acid residue or of certain types which, as the remaining symbols... Agent: Polyphor Ag

20110312880 - Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase: The present invention relates to compounds, in particular, dual antagonists comprising a nucleoside reverse transcriptase inhibitor (NRTI) or a nucleoside competititive reverse transcriptase inhibitor and a non-nucleoside reverse transcriptase inhibitor (NNRTI), linked together using a chemical linker, which may be used to inhibit HIV (HIV-1) reverse transcriptase and in the... Agent:

20110312881 - Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases: The present invention relates to compositions comprising combinations of biologically active proteins linked to extended recombinant polymer, methods of production of the compositions and their use in treatment of metabolic and cardiovascular diseases, disorders and conditions.... Agent: Amunix, Inc.

20110312882 - Methods and compositions for increasing the anaerobic working capacity in tissues: Provided are compositions comprising beta-alanylhistidine peptides and/or beta-alanines, and methods for administering these peptides and amino acids. In one aspect, the compositions and methods cause an increase in the blood plasma concentrations of beta-alanine and/or creatine.... Agent: Natural Alternatives International, Inc.

20110312883 - Neurturin molecules: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of... Agent: Cns Therapeutics, Inc.

20110312885 - Controlled release system and manufacturing method thereof: A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic... Agent: Kaohsiung Medical University

20110312884 - Noggin-derived peptide and use thereof: Disclosed are a noggin-derived peptide and a composition containing the same for promoting hair growth, improving skin conditions, providing anti-inflammatory function, or preventing or treating bone diseases. The disclosed noggin-derived peptide performs a function identical or similar to that of natural human noggin and is superior in stability and skin... Agent: Caregen Co., Ltd.

20110312886 - Tgf-ß and methods of treating ocular and other diseases: Disclosed herein is a method of treating ocular and systemic conditions by administering a TGF-β.... Agent: Allergan, Inc.

20110312887 - Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue: (2-c) DNA encoding a protein or a peptide, the protein or the peptide having an effect of promoting regeneration of tendon-bone junction tissue or ligament-bone junction tissue, and the DNA hybridizing with DNA comprising a base sequence complementary to (2-a) or (2-b) under a stringent condition.... Agent: Kringle Pharma, Inc.

20110312888 - Method of detecting and/or measuring hepcidin in a sample: Methods of isolating and/or analyzing hepcidin by mass spectrometry and methods of quantifying hepcidin are disclosed.... Agent: Amgen Inc.

20110312889 - Sustained release of microcrystalline peptide suspensions: The invention relates to a fluid, milky microcrystalline aqueous suspension of a peptide or peptidomimetic and a counter-ion of a strong proton donor in water, wherein the peptide or peptidomimetic and counter-ion are present in amounts and at a molar ratio sufficient to form the suspension upon mixing and without... Agent:

20110312890 - Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.... Agent: Signature R&d Holdings, LLC

20110312891 - Enamel matrix derivative fraction c: Isolated active compound of a naturally occurring fraction of Enamel Matrix Derivatives (EMD), having at least one of each two N-terminal polypeptide fragments of amelogenin, which are at least 95% identical to an amino acid sequence as shown in SEQ. ID. No:1 and/or 2. The invention relates to the use... Agent: Straumann Holding Ag

20110312892 - Anxiolytic compositions containing alpha s1-casein-derived peptides: The invention relates to pharmaceutical compositions and food products containing peptides derived from the αs1-casein in milk and having benzodiazepine-type activity and particularly, anxiolytic activity.... Agent:

20110312893 - Method for isolating neural cells with tenascin-r compounds: The invention relates to a method for isolating neural cells using tenascin-R compounds, tenascin-R fragments particularly suited for said method and tenascin-R fusion proteins, to recombinant preparation of said tenascin-R compounds, and to a kit for carrying out said method and to the use of said method for preparing high-purity... Agent: Rheinische -friedrich-wilhelms-universit&#xc4 T Bonn

20110312894 - Methods of diagnosing and treating neurodegenerative diseases: The present invention relates to methods of diagnosing, treating and prognosing mental disorders, such as Alzheimer's Disease. In one embodiment, the present invention provides a method of treating Alzheimer's Disease by inhibiting dysfunctional signaling of α7 nAChRs in the medial septum region of an individual.... Agent: Catholic Healthcare West

20110312895 - Dipeptide mimetics of ngf and bdnf neurotrophins: The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective... Agent:

20110312896 - Inhibitors of bcl-2: A purified polypeptide includes about 5 to about 80 amino acids and includes an amino acid sequence corresponding to a portion of SEQ ID NO:1. The polypeptide inhibiting binding of Bcl-2 to IP3 receptors of cells that express IP3R and Bcl-2.... Agent:

20110312897 - Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation: Methods and agents useful for modulating histone proteolysis, stem cell differentiation, and gene transcription and for treating cancer are disclosed. Antibodies or antigen binding fragments that selectively bind to histone-3 cleavage products and are useful for diagnosing cancer and monitoring a subject's response to cancer treatment are also disclosed.... Agent: The Rockefeller University

20110312898 - Prophylactic / therapeutic agent for cancer: A prophylactic/therapeutic agent for androgen-independent cancer is provided. A prophylactic/therapeutic agent for androgen-independent cancer includes a metastin derivative, and is particularly useful as a prophylactic/therapeutic agent for androgen-independent cancer, in particular, androgen-independent prostate cancer.... Agent: Takeda Pharmaceutical Company Limited

20110312899 - Hdl particles for delivery of nucleic acids: Disclosed are high density lipoprotein-nucleic acid particles, wherein the particles include (a) an apolipoprotein; (b) a nucleic acid component comprising a therapeutic nucleic acid segment; and (c) a polypeptide comprising a positively charged region, wherein the positively-charged region of the polypeptide associates with the nucleic acid component. Also disclosed are... Agent: Board Of Regents Of The University Of Texas System

20110312900 - Bche albumin fusions for the treatment of cocaine abuse: A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of... Agent:

20110312901 - Methods of inhibiting cell death or inflammation in a mammal by administering a bcl protein: In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods... Agent:

20110312902 - Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke: The present invention relates generally to the use of γ-glutamyl antioxidants, particularly γ-glutamyl-cysteine, as cytoprotective agents to prevent reperfusion injury (i.e., hemorrhagic transformation) of the blood-brain barrier during reperfusion following an ischemic stroke. The γ-glutamyl antioxidants can be used alone or used in combination with an agent which inhibits the... Agent: Rosalind Franklin University Of Medicine And Science

20110312903 - Fluorination of organic compounds: Methods for fluorinating organic compounds are described herein.... Agent:

20110312904 - Compounds, compositions and methods for reducing toxicity and treating or preventing diseases: The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a... Agent: Trustees Of Columbia University In The City Of New York

20110312905 - Stimulus-triggered prodrugs: Set forth herein, inter alia, are compositions and methods for treating diseases with prodrugs. Provided herein are prodrug compositions for inhibiting the function of proteins, compositions and methods for treating diseases associated with oxidative compounds, oxidatively-sensitive prodrugs of inhibitors of metalloproteases. and methods of inhibiting metalloproteases using oxidatively-sensitive prodrugs.... Agent: The Regents Of The University Of California

20110312906 - Treatment or reduction of menopausal symptoms: There is described a method for the treatment or prevention of menopausal symptoms or osteoporosis wherein there is administered to a subject in need of such treatment a therapeutically effective amount of the isotlavone formononetin, or a method for the treatment or prevention of menopausal symptoms wherein there is administered... Agent: Novogen, Inc.

20110312907 - Polymorphisms predictive of anthracycline- induced cardiotoxicity: Provided are methods, nucleic acids, and arrays for assessing the susceptibility of a subject to the development of cardiotoxicity in response to receiving one or more anthracycline compounds, the method including determining the presence or absence of one or more polymorphisms, wherein the presence or absence of one or more... Agent:

20110313018 - Cancer related gene, lgn/gpsm2: The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the LGN/GPSM2 gene. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment or prevention of cancer and methods for treating breast cancer. Moreover, the... Agent: Oncotherapy Science, Inc.

20110313022 - Compositions and methods for diminishing viral infection and inflammation associated with viral infection: The invention relates to compositions and methods for preventing and diminishing virus infection. The invention further relates to compositions and methods for diminishing inflammation associated with viral infection. The invention also relates to compositions and methods for interfering with TLR activation, and thereby diminishing inflammation associated with viral infection.... Agent: Philadelphia Health And Education Corporation D/b/a Drexel University College Of Medicine

20110313021 - Method to rapidly identify critical p53 target genes that can be utilized for therapeutic intervention: The majority of human cancers inactivate the p53 tumor suppressor network, and consequently, p53 is one of the most studied proteins in cancer biology. Peering into the intricacies of the p53 network should provide insight into the etiology of cancer, which may lead to the identification of molecular targets for... Agent:

20110313025 - Methods and compositions involving mirna and mirna inhibitor molecules: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors... Agent:

20110313019 - Oligomeric compounds and methods: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.... Agent: Isis Pharmaceuticals, Inc.

20110313024 - Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression and/or activity. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid... Agent:

20110313023 - Rnai modulation of rsv and therapeutic uses thereof: The present invention is based on the in vivo demonstration that RSV can be inhibited through intranasal administration of iRNA agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently. Based... Agent:

20110313017 - Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates: The present invention provides polyoxaline-dialkyloxypropyl conjugates (POZ-DAA), SNALP compositions comprising POZ-DAA conjugates and methods of using such SNALP compositions to introduce a therapeutic agent, such as a nucleic acid, into a cell (e.g., for the treatment of a disease or disorder).... Agent: Protiva Biotherapeutics, Inc.

20110313016 - Treatment of intestinal conditions: Methods and compositions for the treatment of intestinal disorders, such as IBD and Crohn's disease, are disclosed. Preferred compositions include siNA. Also disclosed is a method of specifically targeting siNA to treat intestinal disorders by intrarectal administration of siNA compounds.... Agent: Sylentis S.a.u.

20110313020 - Usirna complexes: This disclosure provides double-stranded RNA complexes having one or more hydroxymethyl substituted nucleomonomer(s) in the passenger strand (or sense strand) of an RNA complex. RNA complexes of the disclosure may be useful for therapeutic applications, diagnostic applications or research applications. RNA complexes include short interfering RNA complexes (siRNA) capable of... Agent: Marina Biotech, Inc.

20110313029 - Diagnostic and therapeutic uses of gnptab, gnptg, and nagpa in stuttering: The allelic variants or mutations in three genes: GNPTAB, GNPTG and NAGPA, that correlate with stuttering in humans, as well as the encoded mutated polypeptides and related vectors, host cells, antibodies, antibody-producing cell lines and methods of diagnosing, prognosticating and treating stuttering are provided.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20110313026 - Dna and proteins or peptides specific of bacteria of the neisseria meningitidis species, methods for obtaining them and biological applications thereof: The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in Neisseria meningitidis, but not in Neisseria gonorrhoeae, or in Neisseria lactamica except the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110313027 - Methods and substances for stimulating muscle regeneration: The invention is concerned with the field of muscle growth and regeneration. More particularly, the invention provides novel methods, substances and uses for facilitating the growth or regeneration of skeletal muscles. The methods, uses and substances of the invention are useful in the treatment or prevention of degenerative-regenerative muscular disorders... Agent:

20110313031 - Olioodeoxynucleotide and its use to induce an immune response: wherein the central CpG motif is unmethylated, R is A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a... Agent: The Govt. Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health & Human Services

20110313030 - Pkr activation via hybridization chain reaction: The present application relates to the use of hybridization chain reaction (HCR) to form double stranded RNA polymers in the presence of a target, such as a nucleic acid associated with a disease or disorder. The RNA polymers are preferably able to activate the RNA-dependent kinase PKR. Activation of PKR... Agent: California Institute Of Technology

20110313028 - Suppressor of ap-1: Methods, compositions, and therapeutic products for use in the field of oncology and specifically, for the treatment of cancer and other diseases in which SARI is ameliorative or therapeutic and/or small molecule screening for anti-cancer drugs are provided. Cancer specific gene expression using the CCN1 promoter, which is negatively regulated... Agent: Virginia Commonwealth University

20110312908 - Small molecule myristate inhibitors of bcr-abl and methods of use: The present invention provides novel heteroaryl compounds that are linked to an aryl group via an amine linker. Such compounds are useful for the treatment of cancers.... Agent: Dana-farber Cancer Institute, Inc.

20110312909 - Therapeutic combination comprising a cdks inhibitor and an antineoplastic agent: The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of alkylating or alkylating-like agents, antimetabolite agents and topoisomerase I inhibitors, wherein the active ingredients are present in... Agent: Nerviano Medical Sciences S.r.l.

20110312910 - Pharmaceutical composition based on a hepatoprotector and a prebiotic, and production and application thereof: The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic... Agent:

20110312911 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck Sharp & Dohme Corp.

20110312913 - Method and pharmaceutical to treat spinal discs: Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a solution is injected into the disc. The solution includes chondroitin sulphate, glucosamine HCl, and dextrose. The solution may optionally include dimethyl sulfoxide and/or an anesthetic such as bupivicaine.... Agent:

20110312912 - Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently... Agent: Anika Therapeutics, Inc.

20110312914 - Carbon monoxide removal agent: The present invention provides a carbon monoxide removal agent that can be easily administered to a patient by injection or orally. The carbon monoxide removal agent of the present invention contains, as an active ingredient, an inclusion complex in which a cyclodextrin dimer represented by chemical formula (1) below includes... Agent: The Doshisha

20110312915 - Novel cosmetic compositions: The present invention is concerned with novel cosmetic or pharmaceutical compositions. More particularly, the invention is concerned with novel cosmetic or pharmaceutical compositions for treating or preventing any symptoms caused by negative developments of the physiological homeostasis of healthy skin, as well as for the promotion of hair growth and... Agent: DsmIPAssets B.v.

20110312916 - Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens: Prodrugs of C-17-heterocyclic-steroidal drugs providing improved oral bioavailability and pharmacokinetics are described. The drugs are inhibitors of human CYP 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (AR), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such... Agent: Tokai Pharmaceuticals, Inc.

20110312917 - Cleaning composition for treating tissue for transplantation derived from human/animal: The present invention relates to a cleaning composition for removing cellular components from tissue for transplantation derived from humans and animals. More particularly, the present invention relates to a cleaning composition for treating tissue for transplantation comprising a polyoxyethyleneglycol C14-C20alkyl ether as a first protein solubilizing component, a C6-C8alkylphenol polyethoxylate... Agent: Cg Bio Co., Ltd.

20110312920 - Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same: Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections... Agent:

20110312919 - Inhibitors of tyrosine kinase receptor dimerization: The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised... Agent: Washington University

20110312918 - Method for identifying agents for inhibiting cell motility and invasiveness: The present invention provides a novel mechanistic pathway and methods related to this pathway for the identification of compounds for the treatment of diseases involving cell proliferation, invasion and/or metastasis such as cancer. In particular, the instant invention relates to the phosphatase activity of Eya and the Eya-Six complex as... Agent: Children's Hospital Medical Center

20110312921 - N-myristoyl transferase inhibitors: The present invention relates to N-heterocyclic sulphonamide compounds, in particular pyrazole sulphonamide compounds, and their use as N-myristoyl transferase inhibitors.... Agent:

20110312922 - Edta resistant s100a12 complexes (erac): The present invention relates to the discovery of a new protein complex in human biological materials that can be used for diagnostic and other purposes. The invention further relates to products, methods and uses related to said protein complex.... Agent: Erac As

20110312923 - Formulas comprising highly soluble elements and vitamin for the prevention and amelioration of osteoporosis: The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D3. The acetate salts could be extracted from natural sources such as pearls, coral, and oyster or compounded using synthetic materials. The dosage and ratio of calcium to magnesium was estimated... Agent:

20110312925 - Methods of treating or preventing estrogen-related diseases: Methods for treating or reducing the likelihood of acquiring estrogen-related (e.g. estrogen-exacerbated) diseases including endometriosis include administering to a patient a selective estrogen receptor modulator (SERM), in combination with inhibiting ovarian secretions, e.g., by administering an LHRH agonist or antagonist. In some embodiments, a precursor of sex steroids, said precursor... Agent: Endorecherche, Inc.

20110312924 - Novel steroidal cyp17 inhibitors/antiandrogens: wherein: the ABCD ring structure is the nucleus of a steroid, or an analog thereof; X is a group capable of coordinating a heme group of CYP17, and Y is an hydroxyl functionality, a suitable ester, or a prodrug group, for the treatment of urogenital and/or androgen-related cancers, such as... Agent: Tokai Pharmaceuticals, Inc.

20110312926 - 2-(n-substituted piperazinyl) steroid derivatives: Novel chemical agents are described herein. More specifically, 2-(N-substituted piperazinyl) pregnane and 2-(N-substituted piperazinyl) androstane derivatives exhibiting cytotoxicity on a variety of cancer cell lines are disclosed herein.... Agent: Universite Laval

20110312927 - Progesterone containing oral dosage forms and related methods: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral... Agent:

20110312928 - Progesterone containing oral dosage forms and related methods: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral... Agent: Lipocine Inc.

20110312929 - Treatment of vaginal atrophy in women with cardiovascular pathology risk: The present invention relates to the use of estriol in the preparation of a pharmaceutical formulation for vaginal administration with the capacity to self-limit the absorption of estriol, for the prevention and/or the treatment of urogenital atrophy in women said women having a high probability of suffering from a cardiovascular... Agent: Italfarmaco, S.a.

20110312933 - Oxyindole derivatives with motilin receptor agonistic activity: The present invention relates to novel oxyindole derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the motilin receptor (GPR38).... Agent:

20110312930 - Aryl compounds with aminoalkyl substituents and their use: The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic... Agent: Bayer Schering Pharma Aktiengesellschaft

20110312931 - Glycine transporter-1 inhibitors, methods of making them, and uses thereof: e

20110312932 - Therapeutic uses of compounds which selectively modulate the cb2 receptor:

20110312935 - 1h-benz imidazole-5-carboxamides as anti-inflammatory agents: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family... Agent: Boehringer Ingelheim International Gmbh

20110312934 - 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine derivatives, preparation thereof, and therapeutic application thereof: The invention relates to 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives of the general formula (I) where: R2 is a C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-4-alkyl, C1-4-alkyloxy-C-M-alkyl, C3-7-cycloalkyloxy-C1-4-alkyl>C3-7-cycloalkyl-C1-4-alkyloxy-C1-4-alkyl, hydroxy-C1-6-alkyl, C1-4-fluoroalkyl group; R3 is a hydrogen atom or a substituent selected from halogen atoms and the C1-3 alkyl, —NR4R5, hydroxyl or C1-4 alkyloxy groups; A is a C1-7-alkylene group... Agent: Sanofi-aventis

20110312936 - Cyclohexyl-azetidinyl antagonists of ccr2: wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of... Agent:

20110312937 - 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds: wherein A, B and R1 to R7 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic... Agent:

20110312938 - Pyrrolopyridine carboxylic acid derivatives: Disclosed are compounds and pharmaceutically acceptable salts of Formula (I) wherein R1, R2, R3, and RN are as defined herein. Compounds of Formula (I) are useful in the prevention and/or treatment of neurological and psychiatric disorder, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the disclosure and... Agent: Ironwood Pharmaceuticals, Inc.

20110312939 - New chemical compounds: The present invention relates to new compounds of general formula (I), wherein the groups R1 to R3, X1, X2, X3 and L1 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof in such a... Agent: Boehringer Ingelheim International Gmbh

20110312940 - Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (p13-kinases) inhibitor: The present invention encompasses compounds of general formula (1) wherein R1 to R4, A, X, m and k are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned... Agent: Boehringer Ingelheim International Gmbh

20110312941 - 1,4-disubstituted piperidines as vasopressin receptor via antagonists: The present invention provides compounds of formula (1) compositions comprising such compounds; the use of such compounds in therapy (such as in the treatment of dysmenorrhoea); and methods of treating patients with such compounds; wherein A and G are as defined herein.... Agent: Vantia Limited

20110312942 - Aurora kinase inhibitors for inhibiting mitotic progression: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.... Agent: Millennium Pharmaceuticals, Inc.

20110312943 - Aurora kinase inhibitors for inhibiting mitotic progression: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.... Agent: Millennium Pharmaceuticals, Inc.

20110312944 - Heterocyclic compounds which modulate the cb2 receptor: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Boehringer Ingelheim International Gmbh

20110312945 - Crth2 modulators: Modulators of CRTH2, particularly antagonists of CRTH2, that are useful for treating various disorders, including asthma and respiratory disorders are disclosed. The compounds fall within a genus described by formula I... Agent:

20110312946 - Combination therapy for the treatment of diabetes: The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.... Agent: Theracos, Inc.

20110312947 - Method of improving ß-adrenergic receptor function: The present invention relates to a method of increasing the sensitivity of a hyperinsulinemic patient to the anti-obesity and antidiabetic effects of a β adrenergic receptor (βAR) agonist. The method comprises administering to the patient the βAR agonist and an agent that reduces plasma insulin levels and thereby increases the... Agent: Duke University

20110312948 - Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same: Novel crystalline form of perphenazine 4-aminobutyrate trimesylate and a process of producing the same are disclosed. The novel crystalline form is characterized by a unique XRPD pattern and a DSC that exhibits an endothermic peak at a relatively high temperature (e.g., higher than 209° C.). Also disclosed are a process... Agent:

20110312949 - Pharmaceutical use of substituted amides: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture... Agent: High Point Pharmaceuticals, LLC

20110312950 - Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula Formulas (I), (Ia1-20), (Ib1-20), (Ic1-20), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the... Agent: Boehringer Ingelheim International Gmbh

20110312953 - Anthranilic acid derivatives: i

20110312951 - C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof: Disclosed are C-ring modified tricyclic benzonaphthiridinone compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.... Agent: Merck Patent Gmbh

20110312954 - Mineralocorticoid receptor antagonist and methods of use: The present invention provides a compound of the formula: Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering... Agent: Eli Lilly And Company

20110312952 - Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis;... Agent: Merck Canada Inc.

20110312955 - Triazine compounds as pi3 kinase and mtor inhibitors: and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this... Agent: Wyeth LLC

20110312956 - Arylindenopyrimidines with reduced herg channel binding: d

20110312957 - Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors: The invention provides compounds of formula A or B which are useful in the treatment of a subject infected with HIV.... Agent: Csir

20110312958 - Modulators of atp-binding cassette transporters: Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Vertex Pharmaceuticals Incorporated

20110312959 - Derivatives of azaindoles as inhibitors of protein kinases abl and src: The present invention relates to compounds of general formula I and use thereof as inhibitors of protein kinases AbI and Src and the method of production thereof. The present invention also relates to pharmaceutical compositions and medici-nal products comprising these compounds.... Agent:

20110312960 - Pyrazine derivatives and use as pi3k inhibitors: The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.... Agent: Merck Serono Sa

20110312961 - 2,5-disubstituted morpholine orexin receptor antagonists: The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with... Agent:

20110312962 - Novel 2-morpholino-3-amido-pyridine derivatives and their medical use: The present application discloses novel 2-morpholino-3-amido-pyhcline derivatives and their use as modulators of the voltage gated Kv7 (KCNQ) potassium ion channels in the treatment of pain, neurodegenerative disorders, urinary incontinence, etc. . . . . In other aspects the application discloses the use of these compounds, in a method for... Agent: Neurosearch A/s

20110312964 - Cysteine protease inhibitors: e

20110312963 - P38 map kinase inhibitors:

20110312965 - Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties: The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumours, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.... Agent:

20110312966 - Dithiinopyridazinone derivates: The present invention relates to new dithiinopyridazinone derivatives, to processes for preparing them, to their use for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to crop protection compositions comprising these dithiinopyridazinone derivatives.... Agent: Bayer Cropscience Ag

20110312967 - Bridged and fused antidiabetic compounds: This invention provides for certain bridged and fused compounds of the formula G-L-A I or a pharmaceutically acceptable salt, ester of solvate thereof wherein: A is: (I) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free... Agent: Schering Corporation

20110312968 - Method for optimizing the treatment of chronic myeloid leukemia with abl tyrosine kinase inhibitors: The present invention relates to a method tor evaluating patterns to help-optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. Specifically, present invention relates to SHP1 and/or SHP2 as a biomarker for CML patients.... Agent:

20110312969 - Compounds for treating cancer: Compounds of general formula (I): wherein R1, R2, R3, R4, R5, R6, X and Y are as defined herein are inhibitors of Bcl-2 and are useful for treating diseases characterised by abnormal cell growth and/or dysregulated apoptosis.... Agent: Boehringer Ingelheim International Gmbh

20110312970 - Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia: m

20110312971 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders,... Agent: Merck Patentgesellschaft

20110312972 - Substituted 3-benzofuranyl-indol-2-one-3-acetamididopiperazine derivatives, preparation thereof, and therapeutic use thereof: The invention relates to disubstituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives of the general formula (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are such as defined in claim 1, to a method for preparing same, and to the therapeutic use of said compounds.... Agent: Sanofi

20110312975 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders,... Agent:

20110312974 - Heteroaryl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated... Agent: Amira Pharmaceuticals, Inc.

20110312976 - Novel isoindolin-1-one derivative: The present invention relates to a compound represented by formula (I): (wherein R, R2, R3 and R4 each independently represent a hydrogen or halogen atom; R5 and R6 each independently represent a hydrogen atom or lower alkyl or together represent oxo; X represents C(O) or the like; Y represents an... Agent: Msd K.k.

20110312973 - Solid compositions: The present invention features solid compositions comprising amorphous Compound I. A solid dispersion of the present invention also contains a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant. Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically... Agent:

20110312977 - Process for the preparation of voriconazole: The present invention provides a process for preparation of racemic voriconazole in a single reaction vessel. The present invention also provides a process for preparation of voriconazole using racemic voriconazole and the process of making it therewith.... Agent: Glenmark Generics Limited

20110312978 - Pde1 inhibitors for ophthalmic disorders: Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure-lowering... Agent:

20110312979 - Fused pyrrole derivatives as pi3k inhibitors: m

20110312980 - Small-molecule hsp90 inhibitors: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.... Agent: Sloan-kettering Institute For Cancer Research

20110312982 - Cancer treatment method: A method of treating cancer is described including administration of a 4-quinazolinamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolinamines.... Agent:

20110312981 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker SFRS7 which is predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.... Agent:

20110312983 - Deuterium-enriched alogliptin: The present application describes deuterium-enriched alogliptin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110312984 - Stat3 inhibitors: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well... Agent:

20110312985 - Naringenin complexes and methods of use thereof: The invention relates to methods of treatment of hepatitis C, dyslipidemia, insulin resistance, and inflammation, with flavonoid-sugar complexes.... Agent: The General Hospital Corporation

20110312986 - Composition and method for treating overactive bladder: The present specification discloses compounds, compositions including such compounds, kits including such compounds and compositions, and methods of treating an individual suffering from overactive bladder and/or diabetes by administering such compounds or compositions to an individual in need thereof.... Agent: Allergan, Inc.

20110312989 - Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles,... Agent:

20110312987 - Salt of naphthyridine carboxylic acid derivative: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.... Agent: Lg Chemical Ltd.

20110312988 - Sns-595 and methods of using the same: The present invention relates to SNS-595 and methods of treating cancer using the same.... Agent: Sunesis Pharmaceuticals, Inc.

20110312991 - Activated blood coagulation factor inhibitor: An object of the present invention is to provide a novel salt form of a compound that exhibits an inhibitory effect on activated blood coagulation factor X, and is useful as a preventive and/or therapeutic drug for thrombotic diseases, and crystals thereof. The present invention provides N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide tartrate and crystals... Agent: Daiichi Sankyo Company, Limited

20110312990 - Diamine derivatives: The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS),... Agent: Daiichi Sankyo Company, Limited

20110312992 - Inhibitors of c-kit and uses thereof: Compounds and methods useful as inhibitors of c-Kit are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of c-Kit and processes for synthesizing these compounds are also described herein.... Agent:

20110312993 - Amido-tropane derivatives: or to a pharmaceutically acceptable acid addition salt, racemic mixture, or corresponding enantiomer and/or optical isomer thereof. The compounds of formula I are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. The compounds can be used in the treatment... Agent:

20110312994 - Biphenyl derivatives: wherein R1, R2, R3, R4, R5, R6, R7, W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl... Agent: Theravance, Inc.

20110312995 - Bridged and fused heterocyclic antidiabetic compounds: This invention provides for certain bridged and fused heterocyclic compounds of the formula (I) or a pharmaceutically acceptable salt, ester solvate or prodrug thereof wherein: L is: (II) and the other variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as... Agent: Schering Corporation

20110312996 - Novel inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver... Agent: Intermune, Inc.

20110312997 - Inhibition of wdr5 interaction with its binding partners: Peptidomimetics that inhibit the interaction between MLL1 and WDR5 are disclosed. Methods of inhibiting MLL1 activity and methods of treating cancers also are disclosed.... Agent: The Regents Of The University Of Michigan

20110312998 - Methods of making and using stable pharmaceutical compositions comprising ketotifen and naphazoline: Stable compositions comprising ketotifen or a ketotifen salt and methods of preparing such compositions are provided. The pH of the compositions remains at less than about 5 during storage. The methods comprise preparing pharmaceutical compositions comprising ketotifen or a ketotifen salt, and adjusting their pH to less than 5, thus... Agent:

20110312999 - Ketoheteroarylpiperidine and -piperazine derivatives as fungicides: a

20110313000 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20110313001 - Triazole derivatives for treatment of alzheimer's disease: According to the invention there is provided a compound of formula (I): (I) or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions.... Agent:

20110313002 - Tricyclic compounds: c

20110313004 - Deuterated pyridinones: This invention relates to novel substituted pyridinones, their deuterium-modified derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor)... Agent: Concert Pharmaceuticals, Inc.

20110313003 - Gpr120 receptor agonists and uses thereof: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.... Agent: Metabolex, Inc.

20110313005 - Topically applicable pharmaceutical preparation: A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.... Agent: Nycomed Gmbh

20110313006 - Pharmaceutical composition of levamlodipine or pharmaceutically acceptable salt thereof and β receptor blocking agent, and use thereof: A pharmaceutical composition of levamlodipine or a pharmaceutically acceptable salt thereof and a β receptor blocking agent, and a use thereof are provided. An active ingredient of the pharmaceutical composition contains levamlodipine or a pharmaceutically acceptable salt thereof, and a β receptor blocking agent, in which the β receptor blocking... Agent: Shihuida Pharmaceuticals Group (jilin) Ltd

20110313008 - Pentafluorosulpholane-containing antidiabetic compounds: This invention provides for certain pentafluorosulpholane-containing compounds of the formula or a pharmaceutically acceptable salt, ester, solvate or prodrug thereof, wherein the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known as free fatty acid receptor FFAR). This invention further relates... Agent: Schering Corporation

20110313007 - Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator: The present invention provides uses of a glucokinase activator in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, improving insulin sensitivity, enhancing phosphorylation of glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GK activator and metformin. The... Agent: Transtech Pharma, Inc.

20110313009 - Nsaid dose unit formulations with h2-receptor antagonists and methods of use: The present invention generally relates to unit dosage forms of naproxen and H2-receptor antagonists, comprising an immediate-release formulation of naproxen; an immediate-release formulation of an H2-receptor antagonist, and a delayed-burst release formulation of an H2-receptor antagonist.... Agent: Horizon Pharma Usa, Inc.

20110313010 - Combination of local temozolomide with local bcnu: The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more... Agent:

20110313011 - Amino acid compounds: A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting... Agent: Thermolife International, LLC

20110313012 - Amino acid compounds: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group... Agent: Thermolife International, LLC

20110313013 - Triple reuptake inhibitors and methods of their use: Provided herein are bicyclic compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders. Compounds provided herein inhibit uptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more... Agent:

20110313014 - Products comprising n-phenylpropenoyl amino acid amides and uses thereof: The present invention relates to use of a composition comprising N-phenylpropenoyl amino acid amides for the preparation of a product to treat or prevent neurodegenerative disorders, cognitive decline, mild cognitive impairment, dementia, mood disorders, depression, sleep disorders, diseases involving protein aggregation in a human or animal, Alzheimer's disease, macular degeneration... Agent: Nestec S.a.

20110313015 - Fludioxonil derivatives: The present invention relates to the novel fludioxonil derivatives, to processes for their preparation, to their use for controlling unwanted microorganisms, in particular phytopathogenic fungi, or to their use for controlling unwanted broad-leaved weeds and weed grasses of useful plants in each case in crop protection, in the domestic and... Agent: Bayer Cropscience Ag

20110313032 - Competitive inhibitors of type ii dehydroquinase enzyme: The present invention is directed to a compound of formula (I), its diastereoisomers, its enantiomers or its pharmaceutically acceptable salts or solvates, formula (I), to procedures of obtaining the same, to intermediates thereof, and use as competitive inhibitors of the third enzyme of the shikimic acid pathway, the type II... Agent: Universidade De Santiago De Compostela

20110313033 - Ophthalmic uses of s1p receptor modulators: The present invention pertains to the use of a S1P receptor agonist in the manufacture of a medicament in the treatment of an ocular disorder.... Agent:

20110313034 - Neuroactive plant extract from hypericum polyanthemum: The present invention belongs to the field of plant extracts with activity on the central nervous system. Specifically, the plant extract of the present invention is an extract obtained from Hypericum polyanthemum and comprising the compound uliginosin B and/or compounds from the class of benzopyrans such as. The present invention... Agent: Universite De Rouen

20110313035 - Polymorphs of darunavir: The present invention provides novel solvated forms of darunavir and processes for there preparation. The present invention also provides novel process for preparation of darunavir amorphous form and pharmaceutical composition comprising it. Thus, for example, darunavir 2-methyl-2-butanol solvate was dissolved in methylene dichloride, distilled under vacuum at 45° C. to... Agent: Hetero Research Foundation

20110313036 - Crystalline form of y-aminobutyric acid analog: A crystalline form of a γ-aminobutyric acid analog, and methods of preparing same, are provided.... Agent: Xenoport, Inc.

20110313037 - [2.2.2] bicyclic derivatives and methods of use: Administration of a salt of bi-cyclo[2.2.2]octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of seizures in epileptics.... Agent:

20110313038 - Cationic oil-in-water emulsions containing prostaglandins and uses thereof: A colloidal cationic oil-in-water emulsion includes: —a prostaglandin, —an oil having a iodine value ≦2, —one or more surfactants including at least one quaternary ammonium compound, —water, wherein the prostaglandin/total sum of surfactants mass ratio is included between 0.5 and 5. The use of the cationic oil-in-water emulsions for enhancing... Agent: Novagali Pharma Sa

20110313039 - Method for increasing endogenous plasmalogen levels in mammals: The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present... Agent: Nestec S.a.

20110313040 - Organic nutrient salts, methods of preparation and uses: The invention relates to organic nutrient salts, to compositions containing the same, to their preparation as well as their use. Preferred compositions include nutraceutical compositions and dietary supplements for use in neuroprotection and for improving or protecting cognitive and memory function.... Agent: Bellus Health Inc.

20110313041 - Food supplements on the basis of pantothenic acid: e

20110313042 - Amino acid compositions: An amino acid composition is disclosed. The composition includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least one constituent amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine,... Agent: Thermolife International, LLC

20110313043 - Amino acid compositions: Methods for increasing athletic performance, distribution of various Amino Acids to muscles, and solubility of various Amino Acids in a human or animal by administering an amino acid composition that includes: at least one constituent selected from the group consisting of a nitrate, a nitrite, and both; and at least... Agent: Thermolife International, LLC

20110313045 - Histone deacetylases, and uses related thereto: The present invention concerns the discovery that proteins encoded by a family of genes, termed here HDx-related genes, which are involved in the control of chromatin structure and, thus in transcription and translation. The present invention makes available compositions and methods that can be utilized, for example to control cell... Agent: President And Fellows Of Harvard College

20110313044 - Polymorphs of suberoylanilide hydroxamic acid: The present invention is directed to a novel form of suberoylanilide hydroxamic acid and the processes for its preparation.... Agent: Urquima S.a.

20110313046 - Combination therapy with lisdexamphetamine and extended release guanfacine: The present invention relates to treating children and adults with suboptimal responses to Attention Deficit Hyperactivity Disorder (ADHD) monotherapy. More specifically, the present invention relates to a method for treating ADHD in a patient which comprises administering to the patient an extended release guanfacine composition adjunctively with a lisdexamphetamine composition.... Agent:

20110313047 - Delivery system for high concentration of ceramide: The present invention is directed to a delivery system capable of solubilizing high concentrations of ceramide, the system containing: (a) at least one C1-C4 monoalcohol; (b) at least one C6-C22 fatty acid and/or alcohol; and (c) from about 5 to about 14% by weight, based on the weight of the... Agent: L'oreal S.a.

20110313048 - Antimicrobial silicone-based wound dressings: Antimicrobial silicone-based dressings, such as wound dressings, are disclosed. An example dressing comprises a transparent and self-adhesive gel sheet cured from a liquid containing silicone, the sheet having dispersed therein (i) particulates of a chlorhexidine compound that is not soluble in the liquid; and (ii) at least one other antimicrobial.... Agent:

20110313049 - Antibacterial compositions comprising quaternary ammonium germicides and alkamine oxides having reduced irritation potential: Antibacterial compositions having antibacterial effectiveness and reduced eye irritation potential are disclosed. The antibacterial compositions contain a quaternary ammonium compound, an alkamine oxide, a nonionic compound, optional adjuvant materials known in the art, and water. The eye irritation is decreased by decreasing the amount, by weight, of alkamine oxide present... Agent: The Dial Corporation

20110313050 - Solid composition containing the ingredient rasagiline: The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition.... Agent: Ratiopharm Gmbh

20110313051 - Delivery system for topical medications: The present invention is a delivery system comprising a pad and a liquid composition, comprising an insoluble dermatologically active ingredient with a viscosity that permits substantially uniform absorption of the composition onto the pad, and the pad is in then packaged in a sealed container.... Agent:

20110313052 - Composition comprising biodegradable carrier for controlled delivery: The present invention relates to a controlled release medical composition comprising: a powder composition of a binder; a water based liquid; and a medical active pharmaceutical ingredient. In a first embodiment the powder composition comprises at least calcium carbonate of a first phase and calcium carbonate of a second different... Agent: Aduro Material Ab

20110313053 - Thickeners based on polyurethane: e

20110313054 - Branched copolymers, composition and uses:

20110313056 - Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state: There is disclosed aqueous solutions of polyelectrolytes that can be neutralized by increasing temperature, under suitable polyelectrolyte charge state conditions, in order to obtain a homogeneous gel. This can be achieved by adding an appropriate weak electrolyte to the polyelectrolyte so that an increase of temperature will lead to a... Agent: Bio Syntech Canada Inc.

20110313055 - Health characteristic chewy or gummy candy confection: The present invention provides for flavored chewy or gummy candy confections made by making a flavored chewy or gummy candy confection from scratch or adjusting a current flavored chewy or gummy candy confection brand product with our invention. This invention can have a healthier group of edible oils component, unique... Agent: Antioxidant Superfoods, Inc.

20110313057 - Difunctionalized aromatic compounds and polymers therefrom: e

20110313058 - Method and apparatus for limiting growth of eye length: Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision... Agent:

  
12/15/2011 > 142 patent applications in 111 patent subcategories. patent applications/inventions, industry category

20110306539 - Process for making particles for delivery of drug nanoparticles: A process for making particles for delivery of drug nanoparticles is disclosed herein. The process comprises the steps of (a) forming a suspension of drug nanoparticles by mixing a precipitant solution with an anti-solvent solution under micro-mixing environment, where the formed nanoparticles have a narrow particle size distribution; (b) providing... Agent:

20110306540 - Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment: Leptin, leptin analogs, and leptin derivatives are used to treat patients with lipoatrophy. Leptin is effective against conditions of lipoatrophy for both genetic and acquired forms of the disease. A therapeutically effective amount of leptin can be administered in a variety of ways, including subcutaneously and using gene therapy methods.... Agent:

20110306541 - Methods for treating hcv: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.... Agent: Gilead Sciences, Inc.

20110306542 - Novel glp-1 receptor stabilizers and modulators: Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or... Agent: Receptos, Inc.

20110306543 - Combination of insulin with triazine derivatives and its use for treating diabetes: wherein the radicals R1 to R6 have the meaning according to claim 1, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110306544 - Methods and formulations for increasing intestinal function: A method for increasing intestinal function is provided. The method comprising orally and/or enterally administering to a subject in need thereof a therapeutically effective amount of insulin, thereby increasing intestinal function.... Agent: Technion Research & Development Foundation Ltd.

20110306545 - Novel peptides for wound healing: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing.... Agent: Gene Signal International Sa

20110306546 - Compositions for increasing hair growth and decreasing hair loss: The invention provides compositions and methods for increasing hair growth and decreasing hair loss. In one embodiment, the compositions comprise a plurality of hair growth agents. Optionally, the hair growth agents are selected from the group consisting of: IGF-1, FGF-2, FGF-10, PDGF-AA, Wnt-3a, noggin, ephrin-A3, sonic hedgehog (SHH), BMP-6 and... Agent: Alvi Armani Genomics Inc.

20110306547 - Lhrh - antagonists in the treatment of fertility disorders: A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural level S thereby... Agent: Zentaris Gmbh

20110306548 - Stable growth hormone compounds: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.... Agent: Novo Nordisk Health Care Ag

20110306549 - Glp-1 receptor agonists to treat pancreatitis: The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide.... Agent: Amylin Pharmaceuticals, Inc.

20110306550 - Apoe analogs and methods for their use: Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including CNS inflammation, traumatic brain injury, inflammatory bowel disease (also known as Crohn's Disease or ulcerative colitis), cerebral ischemia, atherosclerosis, sepsis, multiple sclerosis and arthritic diseases, Alzheimer's Disease and other brain disorders. The... Agent: Cognosci, Inc.

20110306551 - Modification of factor viii: A Factor VIII derivative of formula (I): wherein: B represents C2 to C10 alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical... Agent: Novo Nordisk A/s

20110306552 - Pyrimidinone inhibitors of lipoprotein-associated phospholipase a2: The present invention relates to new pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 activity, pharmaceutical compositions thereof, and methods of use thereof... Agent: Auspex Pharmaceuticals, Inc.

20110306553 - Methods and uses involving heme binding protein 1: The present invention relates to a method of screening for a modulator of endothelial NO synthase (eNOS) expression, a method of diagnosing a cardiovascular disease in a subject, the use of HEBP-1 for the identification of a medicament for preventing and/or treating a disease involving eNOS dysfunction, particularly a cardiovascular... Agent: Sanofi

20110306554 - Peptide capable of binding to immunoglobulin: The present invention provides a peptide capable of binding to an immunoglobulin, a fusion protein with the peptide, nucleic acids coding for the peptide and for the fusion protein, methods for producing the peptide and the fusion protein, and a composition and means for binding an immunoglobulin, as well as... Agent:

20110306555 - Biologic replacement for fibrin clot: The invention provides composition and methods for repairing a ruptured anterior cruciate ligament.... Agent: Children's Medical Center Corporation

20110306556 - Neuroprotection from brain anoxia and reperfusion injury during stroke and compositions of pkg pathway activators and method of use thereof: A pharmaceutical composition for treating or preventing one or both of neural anoxia and reperfusion injury, which includes a pharmacological activator of the PKG pathway, and methods of treating or preventing medical conditions using a pharmacological activator of the PKG pathway.... Agent: Florida Atlantic University

20110306557 - Neural regeneration peptides and methods for their use in treatment of brain damage: The invention discloses a family of neuronal migration-inducing, proliferation-promoting and neurite outgrowth promoting factors, termed NRP compounds, and provides compositions and methods for the use of NRP compounds in the treatment of brain injury and neurodegenerative disease. NRP-1 compounds induce neurons and neuroblasts to proliferate and migrate into areas of... Agent: Curonz Holdings Company Limited

20110306558 - Prosaposin as a neurotrophic factor: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.... Agent: Myelos Corporation

20110306559 - Methods and compositions for treating neuropathic pain: Compositions and methods for the treatment of neuropathic pain are provided. Compositions of the invention may comprise proteins with a zinc-finger domain fused to a regulatory domain that is capable of either activating or repressing the expression of a target gene involved in neuropathic pain. Alternatively, compositions of the invention... Agent: Sangamo Biosciences, Inc.

20110306560 - Boronic ester and acid compounds, synthesis and uses: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.... Agent: Millennium Pharmaceuticals, Inc.

20110306561 - Complement c3a derived dimeric peptides and uses thereof: whereby a mol percentage of the dimeric peptide in the composition is at least 50 mol percents, or at least 99 mol percents, are disclosed. Further disclosed are processes of preparing such peptide compositions and uses thereof in the treatment of allergic disorders.... Agent: Yeda Research And Devlopment Co. Ltd.

20110306562 - Antisense egfras guanidinium peptide nucleic acid (gpna) oligonucleotides as antitumor agents: A class of antisense agents having a distributed guanidinium peptide nucleic acids (GPNA) backbone which has excellent uptake into mammalian cells, can bind to the target DNA or RNA in a highly sequence specific manner and can resist nucleases and proteases both outside and inside the cell(s) of interest. In... Agent:

20110306563 - Macrolactone derivatives, method for the production thereof and use thereof for the treatment of cancer: The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C1-C6)-alkyl, NH2 or NH—(C1-C6)-alkyl, or X and Y together form a group —O— or wherein X and Y together form a further bond between the C... Agent: Sanofi

20110306564 - Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these: In a dissolving step, in a container 13, a poorly soluble drug and a dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) are dissolved in a volatile organic solvent. In a solid composition forming step following the dissolving step, the organic solvent contained in the solution is removed by evaporation, and... Agent: Hamamatsu Photonics K.k.

20110306565 - Hyaluronic acid containing compositions for treatment of wounds, scars, post-surgical adhesion formation: Pharmaceutical compositions are provided for enhancing the therapeutic effect of biologically active peptides, especially peptides derived from human lactoferrin. The compositions are useful for the treatment and/or prevention of wounds, scars, and post surgical adhesions.... Agent:

20110306566 - Topical skin treatment kits: This invention relates to benzoyl peroxide products for skin treatment, and more particularly to a kit containing a benzoyl peroxide product and a topical moisturizing product. In one embodiment the kit contains BenzaClin® brand clindamycin-benzoyl peroxide gel and Viscontour® brand hyaluronic acid serum.... Agent: Sanofi

20110306568 - Composition containing glucosylglycerol: The invention relates to a composition containing 20 to 80% w/w of glucosyl-glycerol and 0.5 to 20% w/w of one or several mono- and/or disaccharides. Surprisingly, it has been found that an especially aqueous solution containing a high concentration of glucosylglycerol offers exceptionally high long-term stability. The composition has bactericidal... Agent:

20110306567 - Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain: The present invention relates to novel synthetic polysaccharides with antithrombotic activity, having at least one covalent bond with an amino chain, and to the preparation method thereof and to the therapeutic use thereof.... Agent: Sanofi-aventis

20110306569 - Rhamnolipid biosurfactant from pseudomonas aeruginosa strain ny3 and methods of use: The present disclosure relates to an isolated strain of Pseudomonas aeruginosa strain NY3 and compounds produced by this strain having biosurfactant activity, for instance rhamnolipids Rha-C8-C8:1, Rha-C16, Rha-C16:1, Rha-C17:1, Rha-C24:1, Rha-Rha-C6-C6:1, Rha-Rha-C9:1, Rha-Rha-C10:1-C10:1, Rha-Rha-C24, and Rha-Rha-C24:1, as well as compositions of, derived from, comprising, or consisting of one or more... Agent: The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of

20110306570 - Na/k-atpase expression as an indicator for the treatment of cancer: Methods for regulating the expression of Na/K-ATPase and uses thereof, including uses in the diagnosis/prognosis and treatment of cancer, are disclosed.... Agent: University Of Toledo

20110306571 - Methods for treating cancer: Use of a macrolide antibiotic for the manufacture of a medicament for the treatment or prevention of a cancer selected from colorectal cancer, Desmoid tumor, bladder cancer, gastric cancer, and breast cancer, the macrolide antibiotic being one or more of: tylosin, pharmaceutically acceptable salts thereof, and derivatives thereof; erythromycin, pharmaceutically... Agent: Ramot At Tel Aviv University Ltd.

20110306652 - Compositions and their uses directed to huntingtin: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's... Agent: Isis Pharmaceuticals, Inc.

20110306654 - Methods for identifying analgesic agents: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are... Agent:

20110306655 - Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the maturation of dendritic cells. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by maturation of dendritic cells including... Agent:

20110306651 - Rna interference mediating small rna molecules: Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19-23 nt short RNA fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like... Agent: Max-planck-gesellschaft Zur Foerderung Der Wissenschaften E.v

20110306653 - Stabilization method of functional nucleic acid: This invention is intended to enhance and improve the resistance of a single- or double-stranded nucleic acid fragment comprising a base sequence of a functional nucleic acid to degradation by nucleolytic enzymes in a simple and cost-effective manner. The single- or double-stranded nucleic acid fragment comprises, ligated to at least... Agent: Riken

20110306656 - Biologically tolerated low molecular weight polyethylenimines: i

20110306657 - Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents: The invention provides poly(alkyleneimine)-graft-biodegradable polymers and methods for preparing such polymers. The poly(alkyleneimine)-graft-chitosan polymers may optionally contain a targeting element. The poly(alkyleneimine)-graft polymers may be used to deliver a bioactive agent into a cell.... Agent: Agency For Science, Technology And Research

20110306572 - Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr [erbb1] and her-2 [erbb2]: Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.... Agent: Tragara Pharmaceuticals, Inc

20110306573 - Nucleoside derivatives as inhibitors of viral polymerases: Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; wherein R1; R2; R3; Q1 and Q2 are as defined herein, processes for their preparation; pharmaceutical compositions containing them and their use in medicine, in particular the treatment or prevention of HCV infections, are disclosed.... Agent:

20110306574 - Inhibitors of f18+ e coli binding: The present invention relates to blood group A/B/H determinant on Type 1 Core glycosphingolipids chains as recognition point for the FedF protein of F18-fimbriated Enterotoxigenic and verotoxinogenic Escherichia coli and the use of compounds comprising such determinants for the treatment of F18′ E. coli infections in pigs and in screening... Agent: Ghent University

20110306575 - Medical and nutritional applications of highly refined cellulose: The present invention provides a method for using processed-cellulose. Preferably, the processed cellulose is a highly refined cellulose (HRC). The HRC is useful in a number of medical and nutritional applications. These medical and nutritional applications can include, but are not limited to, administering effective amounts of the HRC for... Agent: Regents Of The University Of Minnesota

20110306576 - Compounds and methods relating thereto: A compound of formula (II) or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen; wherein X is selected from O, S and Se; each of R1, R2, R4, R6, R8, R9, R11, R12, R13 and R14 is independently selected from hydrogen, halogen,... Agent: Pharmalucia Limited

20110306577 - Topical skin cream comprising phosphatidylcholine dha and l-tyrosine: The present invention relates to compositions and methods of treating skin. In particular, the present invention relates to the topical application to the skin of compositions for the prevention and/or treatment of damage to skin.... Agent:

20110306578 - Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections: e

20110306579 - Methods of neuroprotection using neuroprotective steroids and a vitamin d: Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D.... Agent: Emory University

20110306580 - Prophylactic agent or therapeutic agent for disease resulting from abnormal bone metabolism: The object of the present invention is to provide a therapeutic agent or a prophylactic agent for a disease resulting from an abnormal bone metabolism, especially osteoporosis which is more effective than conventional agents. Excellent therapeutic effect or prophylactic effect on a disease resulting from an abnormal bone metabolism, especially... Agent: Teijin Pharma Limited

20110306581 - Stable perfluorocarbon emulsion for use as an artificial oxygen carrier: Perfluorocarbon emulsions having a high stability and good oxygen release are disclosed and described. These perfluorocarbon emulsions are typically for use as artificial oxygen carriers. The perfluorocarbon emulsions include a disperse phase of a perfluorocarbon and an emulsion stabilizer, and continuous phase. The emulsion stabilizer can primarily include a poly(ethylene... Agent: University Of Utah Research Foundation

20110306582 - Androgen pharmaceutical composition and method for treating depression: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a depressive disorder, or the symptoms associated with, or related to a depressive disorder in a subject in need thereof. The present invention also relates to a method of administering a... Agent:

20110306583 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent:

20110306584 - Porphyrin catalysts and methods of use thereof: This invention provides a novel class of substituted macrocyclic metallic compounds. The compounds are useful as peroxynitrite decomposition catalysts. Pharmaceutical compositions, and methods of making and using the compounds, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof are also described.... Agent: Trustees Of Princeton

20110306585 - Metal complexes of n-heterocyclic carbenes: The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more... Agent: The Univeristy Of Akron

20110306586 - Nmda receptor modulators and uses thereof: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of... Agent:

20110306588 - Heteroaryloxyheterocyclyl compounds as pde10 inhibitors: Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent:

20110306589 - Nitrogen containing heteroaryl compounds: t

20110306587 - Unsaturated nitrogen heterocyclic compounds useful as pde10 inhibitors:

20110306590 - Aryl- and heteroaryl- nitrogen-heterocyclic compounds as pde10 inhibitors: Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent:

20110306591 - Heteroaryloxycarbocyclyl compounds as pde10 inhibitors: Heteroaryloxycarbocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.... Agent:

20110306592 - Cyclohexyl-azetidinyl antagonists of ccr2: wherein: R1, R2, X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2... Agent:

20110306593 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment,... Agent:

20110306594 - 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same: Provided are novel compound that is useful as a treatment agent or a prophylactic agent for cardiac failure, cardiac failure due to dystelectasis, left ventricular diastolic impairment, angina or cardiac infarct, hypertension, ischemic cardiac disease, and myocardial relaxation impairment recognized in cardiac failure, atrial fibrillation or ventricular arrhythmia, and a... Agent:

20110306595 - Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease: The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent:

20110306596 - Benzazepine inhibitors of gamma-secretase: The present invention relates to new benzazepine inhibitors of gamma-secretase activity, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110306597 - Nicotinamide derivatives: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.... Agent:

20110306598 - Use of the association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor in the treatment of heart failure: e

20110306599 - Indole compounds and pharmaceutical use thereof:

20110306600 - Novel therapeutic compounds: The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.... Agent: Grunenthal Gmbh

20110306601 - Pharmacological modulation of positive ampa receptor modulator effects on neurotrophin expression: Antagonists of group 1 metabotropic glutamate receptors (mGluR) potentiate the effect of positive AMPA receptor modulators on neurotrophin expression, such as brain-derived neurotrophic factor (BDNF). The findings described herein suggest a combinatorial approach for drug therapies, using both positive AMPA receptor modulators and mGluR antagonists, to enhance brain neurotrophism.... Agent: The Regents Of The University Of California

20110306602 - 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases: The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.... Agent:

20110306603 - Large substituent, non-phenolic opioids and methods of use thereof: e

20110306604 - 3- and 6-quinolines with n-attached heterocyclic cgrp receptor antagonists: Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster... Agent:

20110306605 - Coumarin-based compounds for the treatment of alzheimer's disease and cancer: m

20110306606 - Novel 2,6-substituted-3-nitropyridine derivative, method for preparing same, and pharmaceutical composition including same: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing the same, and a pharmaceutical composition including the same for prevention and treatment of osteoporosis. The 2,6-substituted-3-nitropyridine derivative compound of the present invention increases osteoblast activity and effectively inhibits the differentiation of osteoclasts, and thus can... Agent:

20110306607 - Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels: The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110306608 - Compositions and methods for treating vascular, autoimmune and inflammatory diseases: The disclosure provides methods and compositions for the treatment of vascular, autoimmune and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.... Agent:

20110306610 - 9-substituted 8-oxoadenine compound: e

20110306609 - Thiazolopyridine sirtuin modulating compounds: Provided herein are novel sirtuin-modulating compounds of Structural Formula (Ia) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress,... Agent: Sirtris Pharmaceuticals, Inc.,

20110306613 - Chemical compounds: o

20110306612 - Quinazolinone, quinolone and related analogs as sirtuin modulators: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases,... Agent: Sirtris Pharmaceuticals, Inc.

20110306611 - Transcription factor modulating compounds and methods of use thereof: Substituted benzoimidazole compounds useful as anti-infectives that decrease resistance, virulence, or growth of microbes are provided. Methods of making and using substituted benzoimidazole compounds, as well as pharmaceutical preparations thereof, in, e.g., reducing antibiotic resistance and inhibiting biofilms.... Agent: Paratek Pharmaceuticals, Inc.

20110306614 - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors: The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under... Agent: Cardioxyl Pharmaceuticals, Inc.

20110306615 - Novel imidazolidine derivative and use thereof: A is a hydrogen atom, a halogen atom, —ORa or a C1-4 alkyl group which may be substituted by one or more halogen atoms; E is independently selected from a C1-6 alkyl group; m is selected from integers from 0 to 3; R2 and R3 are independently selected from a... Agent: Chugai Seiyaku Kabushiki Kaisha

20110306616 - Novel compounds as cannabinoid receptor ligands: i

20110306617 - Methods and compositions for the production of high concentration alloxazine solutions: Methods are provided for preparation of compositions having an enhanced level of soluble alloxazine, as compared to compositions prepared using conventional techniques. Compositions and a riboflavin form having higher solubility in solution is also provided.... Agent: Caridianbct Biotechnologies, LLC

20110306618 - Jnk modulators: Compounds of formula (I) modulate JNK wherein X1 and X2 are each simultaneously N or CH; X3 is CH—R2 Or N—SO2R, where R is lower alkyl; R1 is aryl or heteroaryl, substituted with 0-3 lower alkyl radicals; R2 is (II), where R3 is H, lower acyl, or an amino acid,... Agent:

20110306619 - 6-phenyl-2-[((piperidin-4-ylmethyl)-piperazin-1yl) or piperazin 1-ylmethyl)-piperidin-1-yl)]-imidazo[2,1-b][1,3,4]thiadiazole derivatives and their use: Provided are heterocyclic compounds, their synthesis and pharmaceutical compositions including them for the treatment of disorders, in particular, cancer.... Agent: Urifer Ltd.

20110306620 - Heteroarylpiperidine and-piperazine derivatives: o

20110306621 - Acylguanidine derivatives: It was confirmed that acylguanidine derivatives, which has the characteristic structure in which the guanidine is bonded to one ring of a naphthalene via a carbonyl group and a cyclic group is bonded to the other ring thereof, exhibit potent 5-HT5A receptor modulating action and excellent pharmacological action based on... Agent:

20110306622 - Methods of treating hematological disorders with quinazolinone compounds in selected subjects: This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that... Agent: Calitoga Pharmaceuticals, Inc.

20110306623 - Novel compounds comprising a 3-(5-alkoxypyrimidin-2-yl) pyrimidin-4(3h)-one structure and drugs that comprise same: Provided are novel compounds that have both angiotensin II receptor-antagonist effects and PPAR-activating effects that are useful as agents for preventing and/or treating hypertension, heart disease, angina, cerebral vascular accident, cerebrovascular disorder, ischemic peripheral circulatory disorder, kidney disease, atherosclerosis, inflammatory disease, type 2 diabetes mellitus, diabetic complication, insulin resistance syndrome,... Agent: Kowa Company, Ltd.

20110306624 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent:

20110306625 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.... Agent: Irm LLC

20110306626 - Imidazolinone derivatives as cgrp receptor antagonists: The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions... Agent:

20110306627 - Morphinan compounds: This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor... Agent: Concert Pharmaceuticals Inc.

20110306628 - Non-peptidyl, potent, and selective mu opioid receptor antagonists: Selective, non-peptide antagonists of the mu opioid receptor (MOR) and methods of their use are provided. The antagonists may be used, for example, to identify MOR agonists in competitive binding assays, and to treat conditions related to addiction in which MOR is involved, e.g. heroin, prescription drug and alcohol addiction.... Agent:

20110306629 - Novel c-1 analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation: The present application relates to novel C-1 substituted analogues of pancratistatin and 7-dexoypancratistatin of Formula (I), pharmaceutical compositions thereof and the use of said compounds of Formula (I) in the treatment of cancer The application also relates to processes for the preparation of said compound of Formula (I) and intermediates... Agent: Brock University

20110306630 - Pharmaceutical compositions comprising colloidal silicon dioxide: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.... Agent:

20110306631 - Triple substituted phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases or conditions, or cancer: The present invention relates to a new family of triple substituted phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition or cancer, their use as a medicament, especially for treating a neurodegenerative or haematological disease or condition or... Agent: Noscira, S.a.

20110306632 - Solid dispersions containing kinase inhibitors: A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and... Agent: Abbott Laboratories

20110306633 - Selective m4 receptor antagonist and its medical use: The present invention provides a selective M4 receptor antagonist, levorotatory demethylated phencynonate or its nontoxic pharmaceutically acceptable salt, a pharmaceutical composition comprising this compound, and a use thereof in the manufacture of a medicament for the treatment of motion dysfunction, such as, tremor, rigor and the like caused by Parkinson's... Agent: Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.l.a.china

20110306634 - Amorphous salt of a macrocyclic inhibitor of hcv: e

20110306635 - Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors: The invention relates specifically to the use of certain 4-[1-(1H-Imidazol-4-yl)-ethyl]-2,3-substituted pyridine compounds and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation.... Agent: Allergan ,inc.

20110306636 - Oxazole pyridine derivatives useful as s1p1 receptor agonists: The present invention provides oxadiazole pyridine derivatives of Formula (I), their use as medicaments and their use for treating multiple sclerosis and other diseases.... Agent: Merck Serono Sa

20110306637 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20110306638 - Benzisoxazole piperidinyl derivatives, pharmaceutical compositions comprising the derivatives and their use: wherein R, X, Y, R′ and T are defined as in the specification. Such compounds have serotonin system modulating effects such as antagonizing effect on 5-HT2A and inhibitory effect on 5-HT reuptake. The compounds have good analgesic and sedative activities with mild toxic and side effects. The invention also relates... Agent: Nhwa Pharma. Corporation

20110306639 - Hydrocarbylidene nitrohydrozinecarboximidamides and a method for making the same, as well as their uses as an insecticide: The present invention discloses hydrocarbylidene nitrohydrozinecarboximidamides and the use thereof as well as a method for making the same. The structural general formula of the compounds are shown in formula I, wherein, R1 is C1-C10 saturated and/or unsaturated aliphatic hydrocarbonyl, benzyl, substituted benzyl, halogenated picolyl, halogenated thiazolyl methyl, tetrahydrofuryl methyl... Agent:

20110306640 - Dabigatran in tumour therapy: The invention relates to the use of dabigatran etexilate of Formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, as well as new medicament formulations for the treatment of tumours.... Agent: Boehringer Ingelheim International Gmbh

20110306641 - Novel 2,6-substituted-3-nitropyridine derivative, method for preparing same, and pharmaceutical preparation including same: The present invention relates to a novel 2,6-substituted-3-nitropyridine derivative compound, a method for preparing same, a pharmaceutical composition for prevention and treatment of osteoporosis including same, applications of same for preparing the therapeutic agent of osteoporosis prevention and treatment, and a method for prevention and treatment of osteoporosis using same.... Agent:

20110306642 - 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention... Agent: Ortho-mcneil-janssen Pharmaceuticals, Inc.

20110306644 - Metalloenzyme inhibitor compounds: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.... Agent: Viamet Pharmaceuticals, Inc.

20110306645 - Novel ortho-substituted arylamide derivatives: e

20110306643 - Triglyceride-containing dormancy sprays:

20110306646 - Fungicidal n-(phenylcycloalkyl)carboxamide, n-(benzylcycloalkyl)carboxamide and thiocarboxamide derivatives: The present invention relates to a N-(Phenylcycloalkyl)carboxamide or N-(Benzylcycloalkyl)carboxamide or its thiocarboxamide derivative of formula (I) wherein A represents a carbo-linked, unsaturated or partially saturated, substituted or non-substituted 5-membered heterocyclyl group, T represents an oxygen or a sulphur atom, B represents a non aromatic carbocycle that can be substituted by... Agent:

20110306647 - Novel polymorphs of sunitinib malate: The present invention provides a novel crystalline form of sunitinib malate, process for its preparation and to pharmaceutical composition containing it. The present invention also provides a process for preparation of sunitinib malate crystal form I. Thus, for example, sunitinib malate was added to water, the mixture was heated to... Agent: Hetero Research Foundation

20110306648 - Apoptosis inhibitor: Disclosed is an apoptosis inhibitor containing an indole derivative represented by the following formula (1) or a salt thereof as an active ingredient, wherein R1 represents a group selected from a hydrogen atom, an alkyl group having 1 to 6 carbon atoms which may have a substituent, an alkenyl group... Agent: Masanori Somei

20110306650 - Process for the preparation of glycopyrronium chloride: The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications.... Agent: Chiesi Farmaceutici S.p.a.

20110306649 - Prodrugs of ion channel modulating compounds and uses thereof: e

20110306658 - Novel compound obtained from gamboge resin, and medical uses of the same: Disclosed herein are seventeen new compounds obtained from an acetone-extracted product of gamboge resin. The seventeen new compounds have activities in inhibiting the growth of tumor/cancer cells.... Agent: Taiwan Sunpan Biotechnology Development Co, Ltd.

20110306659 - Olopatadine formulations for topical nasal administration: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.... Agent: Novartis Ag

20110306660 - Liquid cannabinoid formulations: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.... Agent:

20110306661 - Hydrogel contact lens for sustained drug release and drug release method using hydrogel contact lens for sustained drug release: Disclosed is a sustainedly drug-releasing hydrogel contact lens which can sustainedly release an anionic medicament such as an allergy-treating agent in a mildly irritating and effective manner while achieving vision correction. Specifically disclosed is a hydrogel comprising ionic monomers composed of at least a cationic monomer and an anionic monomer,... Agent: Seed Co., Ltd.

20110306662 - Steroid-derived cyclopamine analogs and methods for using the same in the prevention or treatment of cancer: The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.... Agent: The Wistar Institute And The Trustees Of The University Of Pennsylvania

20110306665 - Cosmetic preparation, method for producing same, composition for cosmetic preparations, cosmetic preparation containing the composition for cosmetic preparations and method for producing same, and cleanser for industrial use: The present invention is related to: (1) a cosmetic preparation including an emulsifying agent, 1,3-propanediol (PDO), and a PDO difatty acid ester, wherein the fatty acids constituting the PDO difatty acid ester are one or two or more types of fatty acids selected from isostearic acid, n-octanoic acid, and n-decanoic... Agent: The Nisshin Oillio Group, Ltd.

20110306664 - Medical dietary composition for treating neurodegenerative diseases: Medical dietary composition for treating neurodegenerative diseases such as Alzheimer, Parkinson's disease, and more preferably adrenoleukodystrophy comprising a mixture of glyceryl trioleate (GTO), glyceryl trierucate (GTE) and at least one conjugated linoleic acid as active ingredient, in combination with suitable excipients and/or diluents.... Agent: Sofedus S.r.l.

20110306666 - New plant derived seed extract rich in essentially fatty acids derived from salvia hispanica l. seed: composition of matter, manufacturing process and use: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable... Agent:

20110306663 - Triheptanoin diet for adult polyglucosan body disease (apbd) treatment: Compositions and methods for the treatment and management of adult polyglucosan body disease (APBD) are disclosed herein. The APBD patients studied in the present invention experienced stabilization of disease progression and limited functional improvement with dietary triheptanoin (C7TG). The amount of C7TG administered to the patient daily for 6-8 months... Agent: Baylor Research Institute

20110306667 - Stabilization of perhydrolases: Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care... Agent:

20110306668 - Construction and screening of solution-phase derived library of fenbufen and ethacrynic acid: A process for synthesizing and screening solution phase derived libraries of fenbufen and ethacrynic acid is provided in the present invention. Compounds in the present invention having cytotoxicities are useful for a variety of therapeutic applications.... Agent: National Tsing Hua University

20110306670 - Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them: p

20110306669 - Rapid onset and short term modafinil compositions and methods of use thereof: Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual.... Agent: Neurohealing Pharmaceuticals, Inc.

20110306671 - Amide derivatives of ethacrynic acid: The invention provides ethacrynic acid derivatives useful to prevent, inhibit or treat a variety of disorders or diseases including cancer and inflammatory disorders.... Agent: The Regents Of The The University Of California

20110306672 - Ceramide-analogous metabolites: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.... Agent: Novartis Ag

20110306673 - Crystalline forms of (1rs,2rs,6rs)-6-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexane-1,3-diol hydrochloride: This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.... Agent: Gruenenthal Gmbh

20110306674 - Pharmaceutical combination: A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one NMDA-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously... Agent: Gruenenthal Gmbh

20110306675 - Compositions and methods for inhibiting nf-kb mediated tumorigenicity and adhesion-dependent survival of cancer cells: Disclosed are compositions and methods for inhibiting NF-κB mediated cellular proliferation and metastasis. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.... Agent:

20110306676 - Method and medicament for pain management: The present invention relates to a method and an apparatus for treating pain in a patient, such as a veterinary patient. The method comprises the step of administering an inhalation anaesthetic at sub-anaesthetic levels to the patient during an anaesthesia of the patient. A suitable agent may be methoxyflurane.... Agent:

20110306677 - Pressure sensitive adhesive composition and pressure sensitive adhesive tape: A pressure sensitive adhesive composition comprising, as a rubber component solid at ordinary temperature, from 10% by mass or more to less than 50% by mass of polyisoprene, from more than 50% by mass to 90% by mass or less of a styrene-isoprene-styrene block copolymer and 0 to 30% by... Agent:

20110306678 - Angle-dependent interference pigments: An angle-dependent interference pigment based on transparent or translucent inorganic flake serving as a substrate is provided. The substrate is coated by coatings (A)+(B)+(C) and optionally coating (D), so as to form a “high-low-high” refractive index layered structure. The coatings (A) and (C) consist of metal oxides, silicate, aluminates and/or... Agent:

20110306679 - Compositions containing agar and a softening agent: The present invention includes a composition that has (a) at least one thermo-reversible polysaccharide chosen from agar; (b) at least one softening agent chosen from a cationic surfactant, an anionic surfactant, a nonionic esterified sugar surfactant, a polyorganosiloxane-containing polymer, a sugar silicone surfactant, and mixtures thereof; (c) at least one... Agent: L'oreal S.a.

20110306680 - Compositions containing agar and esterified sugar surfactants: The present invention is directed to a composition that includes (a) at least one thermo-reversible polysaccharide chosen from agar; (b) at least one softening agent chosen from an esterified sugar surfactant; (c) at least one oil; (d) water; and (e) optionally, at least one emulsifier different from (b), as well... Agent: L'oreal S.a.

  
12/08/2011 > 178 patent applications in 131 patent subcategories. patent applications/inventions, industry category

20110301073 - Novel dna-binding proteins and uses thereof: Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.... Agent: Sangamo Biosciences, Inc.

20110301074 - Protein preparation produced from rape seeds: The protein preparation produced from rape seeds has a protein content of less than 90% based on the dry mass, has a brightness L*, determined according to CIE-L*a*b* color scale, of at least 70 and also has at least water-binding, oil-binding and emulsifying functionality. The method for producing a protein... Agent: Fraunhofer-gesellschaft Zur Forderung Der Angewandten Forschung E.v.

20110301075 - Use of bbi/bbic for treatment of muscular atrophy and degenerative muscle disease: Methods for use of a composition comprising Bowman-Birk Inhibitor (BBI) or a derivative thereof in the treatment and/or prevention of skeletal muscle atrophy, to improve of skeletal muscle function, and to alleviate symptoms and/or slow progression of degenerative skeletal muscle diseases or disorders are provided.... Agent: The Trustees Of The University Of Pennsylvania

20110301076 - Antimicrobial compounds: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is... Agent: Lytix Biopharma As

20110301077 - Method for production of lactoferrin: The invention concerns a method for production of lactoferrin comprising at least the steps of: a) disposing of raw material that have not been treated at a temperature greater than 500 C, b) submitting this raw material to a treatment in order to obtain a solution of Lactenin (LN) or... Agent:

20110301078 - Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems: A group of antimicrobial compounds shows effectiveness for preventing bacterial growth and bio film formation. In particular, the compounds are effective for preventing the growth of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (“MRSA”) bacteria. The compounds include naturally-occurring compounds such as linoleyl ethanolamide, noladin ether, and anandamide, and man-made compounds... Agent:

20110301079 - Neuromedin u receptor agonists and uses thereof: Neuromedin U receptor agonists for use in the treatment of metabolic disorders such as obesity and diabetes are disclosed. In particular, disclosed are neuromedin U receptor agonists that comprise neuromedin S (NMS).... Agent: Merck Sharp & Dohme Corp.

20110301080 - Pharmaceutical compositions: The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.... Agent:

20110301082 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type (2) diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent:

20110301081 - Long-acting formulations of insulins: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.... Agent: Sanofi

20110301083 - Conjugate based systems for controlled drug delivery: Conjugates which comprise a drug and a ligand which includes a first saccharide; wherein the conjugate is characterized in that, when the conjugate is administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the conjugate is sensitive to serum concentration of a second saccharide. Exemplary conjugates and... Agent:

20110301084 - Protracted exendin-4 compounds: Novel protracted exendin-4 compounds and therapeutic uses thereof.... Agent: Novo Nordisk A/s

20110301085 - Protein hydrolysate and plant sterol containing composition for improving serum lipid profile and preventing atherosclerosis: The invention relates to a terapeutical composition comprising a protein hydrolysate and a plant sterol, wherein the weight ratio of the plant sterol to the protein hydrolysate is from 1:0.02 to 1:150. The invention also relates to a terapeutical composition comprising a protein hydrolysate and a synthetic emulsifier and/or a... Agent: Raisio Nutrition Ltd.

20110301086 - Complex polymere amphiphile-pdgf: Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.... Agent: Adocia

20110301087 - Crf1 receptor compounds: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor for corticotrophin releasing hormone (or factor) receptor 1, also known as the CRF1, CRHR1, CRFR1, CRHR, CRF-R. The CRF1 receptor compounds are derived... Agent:

20110301088 - Crystalline ezatiostat hydrochloride ansolvate: Crystalline ezatiostat hydrochloride ansolvate form D is more stable and/or more soluble that various solvated crystalline polymorphic forms of ezatiostat hydrochloride.... Agent: Telik, Inc.

20110301089 - Adiponectin receptor fragments and methods of use: Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in healthy and diabetic patients using C-terminal fragments of adiponectin receptor R1 are also disclosed. In addition, methods are disclosed of increasing the insulin... Agent: Siemens Healthcare Diagnostics Inc.

20110301090 - Skin wound healing compositions and methods of use thereof: A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hsp90α. The composition is topically applied to skin... Agent: University Of Southern California

20110301091 - Compositions and methods for reducing the signs of aging of the skin: Compositions and methods used to reduce the visible signs of aging of the skin by recalibrating the expression of genes, genetic networks, and cellular pathways in the human skin, particularly using combinations of natural compounds that produce synergistic effects on the expression of genes and genetic networks.... Agent:

20110301093 - Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to beclin-1: The present invention relates to antibodies specific for human Beclin-1 protein phosphorylated at position Thr 119 and uses thereof. In particular, these antibodies are useful in diagnosing diseases associated with impaired autophagy including cancer and neurodegenerative diseases. The invention further relates to human Beclin-1 mutated at position 119 with a... Agent: Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science

20110301094 - New tumor suppressor gene, p28ing5: This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The

20110301092 - The use of a non-glycanated polypeptide for treating a cancer: The use of a non-glycanated form of a polypeptide including an amino acid sequence having at least 90% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 and SEQ ID No 2 for manufacturing a medicament for preventing or treating a... Agent: Institut Pasteur De Lille

20110301095 - Methods and compositions for assessing and treating metastasis, metastatic cancer, and potential for metastasis: Disclosed are methods, compounds, and compositions for detection, diagnosis, prognosis, monitoring, treatment, monitoring treatment, and selecting treatment of cancer and metastasis, and for identifying compounds and compositions for such uses. For example, disclosed are methods, compounds, and compositions for detecting a risk of metastasis of cancer in a subject, treating... Agent: Sanford-burnham Medical Research Institute California

20110301096 - Prodrug of an ice inhibitor: Compound I is useful for treating IL-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, Alzheimer's disease, myocardial infarction, congestive heart failure, Huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders,... Agent: Vertex Pharmaceuticals Incorporated

20110301097 - Oral administration of therapeutic agent coupled to transporting agent: The present invention is directed toward a composition for widespread distribution, systemic expression and sustained delivery of a therapeutic agent and to a process for administration of a therapeutic agent via a natural gastrointestinal pathway. More particularly, the invention discloses a composition for the administration of oral gene therapy and... Agent:

20110301099 - Method for enhancing penetration of lipid insoluble medicaments through cell membranes using small s-allyl-containing molecules with phospholipid permeability as carrier molecules: A method and composition that allows for the penetration of lipid insoluble medicaments through cell membranes using small S-Allyl-containing molecules with phospholipid permeable molecules as carrier molecules. S-Allyl-containing compounds can include alliin, allicin, Allium sativum extract and DMSO. Lipid insoluble medicaments can include 1% xylocaine, curcumin, acyclovir, valacyclovir, famciclovir, terbenafin,... Agent:

20110301100 - Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons: A liquid pharmaceutical composition comprising a biodegradable polymer, polyethylene glycol having a molecular weight of less than 600 Daltons, a pharmaceutically active agent and less than 0.5% of an biologically acceptable organic solvent.... Agent: Novartis Ag

20110301098 - Treatment for intimal hyperplasia and related conditions: The present invention provides a method of prevention or treatment of intimal hyperplasia in blood vessel walls, the method comprising the step of administering a therapeutically effective amount of an inhibitor of C5a function to a mammal.... Agent:

20110301101 - T cell immune balance peptides: This invention is related to a peptides mixture. Without the need to consider the patients' genetic background, it can interfere with MHC-pathogenic peptide-TCR formation, which includes the interference with pathogen peptide binding with MHC and pMHC binding with specific TCR, suppression of the immune synapse formation when the specific T... Agent:

20110301102 - Compositions and methods for treating myelodysplastic syndrome: This invention relates to specific treatment regimens for treating myelodysplastic syndrome.... Agent: Telik, Inc.

20110301103 - Methods of treatment: The present disclosure provides a biochemical basis of nephrotic syndrome and provides and explanation for the observed proteinuria and other effects. As a result, the present disclosure provides method for treating and/or preventing nephrotic syndrome as well as methods of alleviating symptoms associated with nephrotic syndrome. The present disclosure further... Agent:

20110301105 - Compositions for proliferation of cells and related methods: We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells such as skin-derived precursors (SKPs)). The invention therefore invention provides compositions, methods, and kits for increasing proliferation of cells, using compounds that... Agent: The Hospital For Sick Children

20110301104 - Transition state structure of orotate phosphoribosyl transferases and uses thereof: Methods are provided for designing a transition state inhibitor of orotate phosphoribosyltransferase (OPRT) and for inhibiting OPRT.... Agent:

20110301107 - Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics: t

20110301106 - Use of icariside ii in manufacture of products for preventing or treating male or female sexual dysfunction: The present invention provides the use of icariside II or extract comprising thereof in manufacture of products for preventing or treating male or female sexual dysfunction, in particular, the use for improving pathological or organical changes in erectile tissues of patients with erectile dysfunction.... Agent: Bjo-biomed Ltd

20110301108 - Materials and methods for sensitizing multidrug resistant cells: Disclosed herein are materials and methods for sensitizing multidrug resistant cancer cells that express ABCG2 and related proteins members of a family of ATP-binding transporter superfamily that mediate drug efflux found in some types of multidrug resistant caner cells. A series of compounds, including (N-(4-chlorophenyl)-2-[(6-{[4,6-di(4-morpholinyl)-1,3,5-tri-azin-2-yl]amino}-1,3-benzothiazol-2-yl)sulfanyl]acetamide), specifically inhibits ABCG2 and can... Agent: Indiana University Research & Technology Corporation

20110301109 - Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof: The present invention relates to a class of phenylpyrimidone compounds, the pharmaceutical composition, the preparation method and the use thereof. More specifically, the present invention relates to a type of phenylpyrimidone compounds of the following formula I, the pharmaceutically acceptable salts or solvates thereof and to the pharmaceutical composition as... Agent: Shanghai Institute Of Materia Medica, Chinese Academy Of Science

20110301110 - Trim33 (tif1gamma) as a new diagnostic marker of chronic myelomonocytic leukemia (cmml): A method for diagnosing a chronic myelomonocytic leukemia (CMML) in a subject includes the steps of (i) determining the level of expression of the Trim33 (tripartite motif-containing 33) gene in a biological sample from the subject, and (ii) comparing the level of expression of the Trim33 gene in the biological... Agent:

20110301222 - Combination therapy for the treatment of cancer: The present invention provides methods of sensitizing cancer cells to docetaxel and inhibiting the growth of various tumors by employing a modified eIF-4E antisense oligonucleotide and docetaxel in combination.... Agent: Isis Pharmaceuticals, Inc.

20110301223 - Compositions and methods for insecticidal control of stinkbugs: Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a Pentatomidae plant pest or a N. viridula, Acrosternum hilare, Piezodorus guildini, and/or Halymorpha halys plant pest, decrease the expression of a target sequence in the pest. In specific embodiments, the decrease... Agent: Pioneer Hi-bred International, Inc.

20110301221 - Diagnosis, prognosis and treatment of glioblastoma multiforme: The present invention in one aspect relates generally to the identification, provision and use of a plurality of biomarkers to provide risk assessment of a subject having glioblastoma multiforme, and products and processes related thereto. In one aspect, a novel plurality of biomarkers as described herein is provided to determine... Agent: Swedish Health Services

20110301224 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that... Agent: City Of Hope

20110301218 - Modified snrnas for use in therapy: The invention relates to a nucleic acid encoding a small nuclear RNA (snRNA), which snRNA is modified so that it contains sequence capable of hybridizing with the 5′ and 3′ splice site junctions and an exonic splicing enhancer of an exon of a pre-mRNA, so that the exon sequence is... Agent:

20110301219 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent:

20110301220 - Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA... Agent:

20110301226 - Compositions and methods for treating hepatic neoplasia: The present invention provides compositions and methods featuring miR-26 microRNA polynucleotides for the diagnosis, treatment or prevention of hepatic neoplasia.... Agent: The Johns Hopkins University

20110301225 - Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells: A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behaviour of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation.... Agent: Index Pharmaceuticals Ab

20110301230 - Gene carrier: Disclosed is a gene carrier composed of a hydrogen-bonding polymer having a polymer chain with hydrogen-bonding sites formed on the polymer chain, in which the polymer chain has a conformation similar to the conformation of a nucleic acid, and particularly, the polymer chain has helix parameters similar to the helix... Agent: Japan Science And Technology Corporation

20110301228 - Gene therapy vector for treatment of steroid glaucoma: The presently disclosed subject matter provides an inducible vector comprising a therapeutic gene. In some embodiments a method is provided for treating steroid glaucoma. In some embodiments a method is provided for preventing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a method is provided for... Agent: The University Of North Carolina At Chapel Hill

20110301229 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: City Of Hope

20110301227 - Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms: This application relates to the use of agents such as expression vectors and nucleic acids encoding integrins α6A or α6B as well as antibodies specific for those integrins which are capable of modulating the ratio between the B and A isoforms of the α6 integrin in the treatment of diseases... Agent:

20110301111 - Cyclic adenosine monophosphates for reducing the formation of adhesions: Provided herein are methods of reducing adhesion formation in a subject, for example, post-surgical abdominal and pelvic adhesions. The methods comprise administering to the subject a compound chosen from one or both of 2′,3′ cyclic adenosine monophosphate, or an analogue or pharmaceutically acceptable salt thereof, able to reduce the formation... Agent:

20110301112 - Fused ring thrombin receptor antagonists: represents an optional double bond, and wherein An, En, Mn, Gn, Jn, R3, n7, R8, R9, R10, R11, R32, R33, X, Y, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method... Agent:

20110301114 - Amphiphile prodrugs: Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attached to a linker, Y1, Y2 or Y3, wherein R... Agent:

20110301113 - Pyridineamine derivatives: This invention relates to novel compounds that are pyrimidineamine derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrimidineamine derivatives that are derivatives of pazopanib. This invention also provides compositions comprising one or more compound of this invention and a carrier, and the use of the... Agent: Concert Pharmaceuticals Inc.

20110301115 - Methods of treating subclinical sun damage: Provided are methods of treating subclinical sun damage and of inducing a chemocytotoxic response in skin. Methods of treating subclinical sun damage include the steps of: topically administering to skin of a patient a composition comprising a chemocytotoxic agent in an amount effective to induce erythema, scaling, crusting, or combinations... Agent:

20110301116 - Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof: The Medical Drugs that comprises a mixture of NSAIDs and sugar that reduce damage of gastrointestinal mucosal induced by NSAIDs is already known. However the mixture is not enough to suppress damage of gastrointestinal mucosal. The inventors invented new molecular compounds with NSAIDs and trehalose. The new molecular compounds effectively... Agent: Next21 K.k.

20110301117 - Cryogenic skin cream and method: A skin cream and skin cream packaging arrangement is disclosed. The arrangement includes, in combination: a skin cream intended to be applied on human skin and found to be most effective when within a determinable temperature range, and a container for containing the skin cream. The container may have a... Agent:

20110301118 - Methods of treatment utilising glucan formulations: The present invention relates to methods for the treatment of skin wounds or lesions, and connective tissue damage or injury, comprising administering to a subject an effective amount of a glucan composition. Also provided are methods for the promotion of wound healing and tissue regeneration.... Agent: Novogen Research Pty Ltd

20110301119 - Pharmaceutical compositions containing fucoidan for stimulating and activating osteogenesis: The present invention relates to pharmaceutical compositions containing fucoidan for stimulating and activating osteogenesis. The compositions according to the present invention contain fucoidan as an active ingredient to increase the activities of alkaline phosphatase and the production of osteocalcin, and to increase the production of bone morphogenetic protein (BMP-2).... Agent: Pukyong National University Industry-academic Cooperation Foundation

20110301120 - Use of a chitosan polymer for heparin neutralization: Use of a chitosan polymer for direct neutralization of heparin in blood and physiological fluids of mammals. The chitosan polymer may be applied as an intravenous solution or for neutralization of heparin in blood or other physiological fluid taken from a donor.... Agent: Uniwersytet Jagiellonski

20110301121 - Hydrogel of polysaccharide derivative: A nerve dysfunction repairing material including a hydrogel of a polysaccharide derivative that has, in a 0.5 wt % aqueous solution, a complex modulus of 1 to 1000 N/m2 and a loss factor of 0.01 to 2.0 as measured at an angular velocity of 10 rad/sec using a dynamic viscoelasticity... Agent: Teijin Limited

20110301123 - Fungicidal heterocyclic amines: n

20110301122 - Heteroaromatic compounds for use as hif inhibitors: The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which... Agent: Bayer Schering Pharma Aktiengesellschaft

20110301124 - Proteasome inhibitors: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.... Agent: Millennium Pharmaceuticals, Inc.

20110301125 - Method for treating macular degeneration: Provided herein are novel and useful methods for preventing, treating, or ameliorating a macular degeneration such as dry macular degeneration, wet macular degeneration and age related macular degeneration in a patient.... Agent: Sanofi-aventis

20110301126 - Pesticidal control device with high load of active ingredient: The present invention relates to a pesticidal control device that includes at least one pesticidal active ingredient, cellulose fibers, and a polymer or polymer matrix. he combination of the cellulose fibers with the polymer allows for a higher loading of liquid pesticidal active ingredients within the pesticidal control device, maintains... Agent: Bayer Animal Health Gmbh

20110301127 - Methods of reducing microbial resistance to drugs: The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity... Agent: Trustees Of Tufts College

20110301128 - Pyrrole derivatives as pharmaceutical agents: Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the... Agent: Exelixis, Inc.

20110301129 - Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and... Agent: Depomed, Inc.

20110301130 - Topical composition for the treatment of actinic keratosis: The invention relates to a topical gel composition for use in the treatment of actinic keratosis comprising (a) an active agent for treatment of actinic keratosis, (b) a keratolytically active agent, (c) a gel former, and (d) an organic solvent.... Agent: Almirall Hermal Gmbh

20110301131 - Drug delivery implants and processes for their preparation: The invention discloses an implant suitable for delivery of at least one drug, the implant comprising a fibrillar collagen matrix having, as measured in Example 1, a viscosity of greater than 100 mPas, optionally greater than 103 mPas, further optionally greater than 106 mPas, still further optionally greater than 109... Agent:

20110301134 - Alkyne antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20110301133 - Compositions of protein receptor tyrosine kinase inhibitors: The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such... Agent: Vm Pharma LLC

20110301132 - Methods of treating urethritis and related infections using fusidic acid: Methods for the treatment and prevention of a bacterial infection caused by Neisseria gonorrhoeae, or Chlamydia trachomatis, or both Neisseria gonorrhoeae and Chlamydia trachomatis, such as urethritis, an ocular infection, or a pharyngeal infection, using fusidic acid, or pharmaceutically acceptable salt thereof, are described.... Agent: Cempra Pharmaceuticals, Inc.

20110301136 - Nitrate esters of corticoid compounds useful as diuretics: The present invention relates to the diuretic effects of nitrate esters of corticoid compounds. A patient in heart failure may be treated by administering a therapeutically effective dosage of a pharmaceutical composition comprising a nitrate ester of corticoid compound as a diuretic having the general formula B—X1—NO2. A method of... Agent:

20110301135 - Stabilization of glucocorticoid esters with acids: The invention relates to nonaqueous pharmaceutical preparations comprising a glucocorticoid ester and an acid, and to the stabilization of glucocorticoid esters in such preparations by acids.... Agent: Bayer Animal Health Gmbh

20110301138 - process to make fusidic acid cream: The invention discloses a process to make dermaceutical cream containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment created using inert gas, preferably nitrogen. The cream produced by the process of the... Agent: Apex Laboratories Private Limited

20110301137 - Dermaceutical gel made using sodium fusidate and a process to make it: The invention discloses a process to make dermaceutical gel containing Fusidic acid which is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment comprising an inert gas, preferably nitrogen. The gel produced by the process of the... Agent: Apex Laboratories Private Limited

20110301139 - Pharmaceutical compositions of cefixime: A pharmaceutical suspension dosage form comprising greater than 80 mg/ml and not more than 150 mg/ml of Cefixime and pharmaceutically acceptable excipients.... Agent: Lupin Limited

20110301141 - Aminopyrimidine derivatives as lrrk2 inhibitors: p

20110301142 - Antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent:

20110301143 - Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R1— substituted heteroaryl, R1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR5R6, C═CR5 or CR13—CR5R6, Y is a bond or —C(O)—, a and b represent an... Agent:

20110301140 - Pyridine carboxamide orexin receptor antagonists: The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent:

20110301146 - Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives: GSK-3beta inhibitors comprising 7-Hydroxy-benzoimidazole-4-yl-methanone Derivatives are provided. For example, the inhibitors have following general formula (I).... Agent: Oncotherapy Science, Inc.

20110301144 - Kinase antagonists: The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.... Agent: The Regents Of The University Of California

20110301145 - Pyridazinones, method of making, and method of use thereof: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity... Agent: Gilead Connecticut Inc.

20110301147 - Modified release preparations containing oxcarbazepine and derivatives thereof: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.... Agent: Supernus Pharmaceuticals, Inc.

20110301148 - Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof: in which n is equal to 0, 1, 2, 3 or 4; m is equal to 0, 1 or 2; o is equal to 0 or 1; X represents a group —CH2, —CH(R′)—, —NH(R′)— or a heteroatom chosen from O and S, it being understood that R′ represents a group... Agent: Sanofi

20110301149 - Compositions and methods for treating alcohol use disorders, pain and other diseases: The present invention provides compounds which antagonize epsilon protein kinase C (PKCε). These compounds have a structural formula (Ia), (Ic) or (II). The present invention also provides pharmaceutical compositions containing these compounds and methods of treating various diseases, conditions, and/or symptoms by using these compounds.... Agent: Vm Discovery Inc.

20110301150 - Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same: Provided are a substituted azole derivative and pharmaceutically acceptable salts thereof, a pharmaceutical composition including an effective amount of the derivative, and a method for treating Parkinson's disease in a mammal including administering an effective amount of the compound to the mammal. The azole derivative of the following Formula (I)... Agent: Sk Biopharmaceuticals Co., Ltd.

20110301151 - Dimeric iap inhibitors: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of... Agent: Tetralogic Pharmaceuticals Corporation

20110301152 - Nicotinic receptor agonists for the treatment of inflammatory diseases: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.... Agent: Universite Laval

20110301153 - Methods of treating cancer: The invention concerns methods of treating cancer comprising contacting said tumors with a chemical inhibitor of glutaminolysis. These inhibitors include amino-oxyacetate, phenylbutyrate, phenylacetate, and 3,7-bis(dimethylamino)-phenazathionium chloride (methylene blue).... Agent: The Trustees Of The University Of Pennsylvania

20110301154 - Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity: The present invention involves new and original sigma receptors Ligands: (Mono-or dialkylaminoalkyl)-γ-butyro-lactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl α-[(adamantyl-1)ben-zyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or di-astereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues with... Agent:

20110301155 - Indazole compounds for activating glucokinase: wherein R1 is an optionally substituted 4- to 7-membered nitrogen-containing heterocyclic group, optionally substituted carbamoyl, or optionally substituted sulfamoyl; R2 is optionally substituted alkyl, optionally substituted alkoxy, an optionally substituted 3- to 7-membered cyclic group, —SR′, —SOR′, or —SO2R′ (R′ is a substituent); R3 is hydrogen, halogen, optionally substituted alkyl,... Agent:

20110301157 - Bicyclic amides as kinase inhibitors: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment... Agent: Novartis Ag

20110301156 - Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions: e

20110301158 - Aryl carbonyl derivatives as therapeutic agents: This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.... Agent: Novo Nordisk A/s

20110301159 - Kinase inhibitor compounds: The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder, and methods of use and compositions thereof.... Agent: University Of Florida Research Foundation, Inc.

20110301160 - Inhibitors of p38 and methods of using the same: In general, the present invention relates to compounds capable of inhibiting p38 in vivo or in vitro, and methods for treating conditions associated with p38 activity or cytokine activity.... Agent: Arqule, Inc.

20110301162 - Aurora kinase modulators and methods of use: wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinase proteins. For example, the compounds are capable of modulating Aurora kinase thereby... Agent: Amgen Inc.

20110301161 - Benzimidazole inhibitors of leukotriene production: e

20110301163 - Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders: Described herein are methods of inhibiting methionine aminopeptidase or SirT1, inhibiting angiogenesis, and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, SirT1 and/or angiogenesis, wherein a compound of the invention is administered to a subject.... Agent: The Johns Hopkins University

20110301164 - Method of administering ophthalmic fluids: A method is provided of treating an eye with ophthalmologically active compounds, particularly with intra-ocular pressure lowering (IOP) compounds, where a dose of 5-15 microliters is delivered at a standard concentration.... Agent:

20110301165 - Method for treating and preventing arthritis: wherein X is selected from the group consisting of hydrogen, halo, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano and nitro; are used to treat or prevent arthritis including rheumatoid arthritis.... Agent: Southern Research Institute

20110301166 - Method for the prevention of thromboembolic disorders: A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders, such as cerebral infarction (stroke) or myocardial infarction, by administering levosimendan or its metabolite (II) or any of their pharmaceutically acceptable salts to a mammal in need of such prevention.... Agent: Orion Corporation

20110301167 - Pyrazolo [4,3-c] cinnolin-3-one m1 receptor positive allosteric modulators: The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical... Agent:

20110301172 - Combination of dpp-iv inhibitor, ppar antidiabetic and metmorformin: for simultaneous, separate or sequential use, especially in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more particular type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; the... Agent:

20110301168 - Cycloalkane[b]azaindole antagonists of prostaglandin d2 receptors: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20110301170 - Inhibitors of jnk: s

20110301171 - Inhibitors of jnk:

20110301169 - Therapies for treating cancer using combinations of cox-2 inhibitors and antimetabolites: A method for treating a subject having cancer, comprising administering to the subject, a therapeutically effective amount of a combination comprising a 1,2-diphenylpyrrole derivative or the respective pharmaceutically acceptable salt, solvate, polymorph or prodrug and an anti-metabolite.... Agent:

20110301173 - 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the... Agent: Takeda Pharmaceutical Company Limited

20110301174 - 1-heterocyclylsulfonyl, 3-aminomethyl, 5- (hetero-) aryl substituted 1-h-pyrrole derivatives as acid secretion inhibitors: The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity and the like. The present invention provides a compound represented by the formula (I) wherein R1 is a nitrogen-containing monocyclic heterocyclic group optionally condensed with a benzene ring or a heterocycle, the... Agent: Takeda Pharmaceutical Company Limited

20110301175 - 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors: The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such... Agent:

20110301176 - Imidazothiazole derivatives having proline ring structure: There is provided compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity. Compounds include imidazothiazole derivatives that can inhibit interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity.... Agent:

20110301177 - Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative: The present invention relates to a suspension formulation containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate, to a capsule pharmaceutical dosage form containing said suspension formulation, to a process for preparing said suspension formulation, to a process for preparing said capsule comprising said suspension formulation and to the packaging material for the finished... Agent: Boehringer Ingelheim International Gmbh

20110301179 - Naphthamides as anticancer agents: e

20110301178 - Pyrazinyl carboxamides as fungicides: This present disclosure is related to the field of pyrazine carboxamides and their derivatives and the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20110301181 - Halogen-substituted compounds: in which the radicals A1, A2, A3, A4, Lm, Q, R1, T and U have the meaning given in the description and to the use of the compounds for controlling animal pests. In addition, the invention relates to processes and intermediates for the preparation of the compounds according to formula... Agent: Bayer Cropscience Ag

20110301180 - Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration: It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated... Agent: Stanford University

20110301182 - Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for improving glycemic control in type 2 diabetes patients with inadequate glycemic control despite metformin therapy.... Agent: Boehringer Ingelheim International Gmbh

20110301183 - Chemical synthesis of a highly potent epothilone: A highly active synthetic epothilone compound whose activity exceeds that of either epothilone EpoA or EpoB when assayed as a cytotoxic agent against a cancer cell line is disclosed as is a pharmaceutical composition containing the synthetic epothilone.... Agent:

20110301184 - Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor: A pharmaceutical combination comprising an mTOR inhibitor and a Raf kinase inhibitor and its use.... Agent: Novartis Ag

20110301185 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one... Agent: Smithkline Beecham (cork) Limited

20110301186 - Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease: This invention is directed to methods and compositions for the treatment of cardiovascular disorders. Specifically, the invention is directed to compositions comprising vitamin E, statins and/or glutathione peroxidase mimetics; methods of treating diabetic patients expressing the Hp-2-2 haptoglobin genotype; a method of inhibiting or suppressing a cardiovascular disorder in a... Agent:

20110301187 - Bis [o-(14-benzoylaconine-8-yl)] esters: The present invention concerns novel compounds having the structure (I). Another object of the invention is the use of compounds (I) for the fabrication of a medicament which is used for the treatment of tumour diseases.... Agent:

20110301188 - Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents: This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for... Agent: Exelixis, Inc.

20110301189 - Stable pharmaceutical compositions of rapamycin esters: A stable pharmaceutical compositions of Rapamycin Esters, in particular Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid that is free of antioxidants and a process of preparing the same.... Agent: Fresenius Kabi Oncology Ltd.

20110301190 - Polymorphic forms of a gabaa agonist: The present invention is directed to novel polymorphic forms of the compound 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrate (gaboxadol monohydrate). The invention is further concerned with pharmaceutical compositions containing the polymorphic forms as an active ingredient, methods for treatment of disorders susceptible to amelioration by GABAA receptor agonism with the polymorphic forms, and processes... Agent: H. Lundbeck A/s

20110301191 - Methods of treatment using selective 5-ht2a inverse agonists: Compounds and methods are provided for the treatment of disease conditions in which modification of serotonergic receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.... Agent:

20110301192 - Inhibitors of cyclin kinase inhibitor p21: The present invention provides compounds that inhibit cyclin kinase inhibitor p21, such as compounds of formula I. The present invention also provides compositions including compounds of Formula I and a pharmaceutically acceptable excipient. In addition, the present invention provides methods of inhibiting cyclin kinase inhibitor p21 and of treating cancer.... Agent: The Regents Of The University Of California

20110301194 - Method for determining treatment efficacy: The present invention provides a method for determining the efficacy of a c-Met inhibitor in treating a cell proliferative disorder, comprising: a) administering to a subject in need thereof a therapeutically effective amount of the c-Met inhibitor, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, either alone or in... Agent: Arqule, Inc.

20110301193 - Methods and compositions of targeted drug development: Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited... Agent:

20110301195 - Triazolothiadiazole inhibitor of c-met protein kinase: The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.... Agent:

20110301196 - Trypsin-like serine protease inhibitors, and their preparation and use: The invention provides compounds that are effective as inhibitors of human plasmin and plasma kallikrein, and that are useful for the prevention of blood loss and as components of fibrin adhesives. The invention further provides methods of making and using the compounds.... Agent: The Medicines Company (leipzig) Gmbh

20110301197 - Bis(difluoromethyl)pyrazoles as fungicides: e

20110301198 - Compositions and methods for treating myelodysplastic syndrome: This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.... Agent: Telik, Inc.

20110301199 - Compositions and methods for treating myelodysplastic syndrome: This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof... Agent: Telik, Inc.

20110301200 - Thyroid receptor ligands: The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta (TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable... Agent: Cadila Healthcare Limited

20110301201 - Dabigatran for percutaneous interventional cardiac catheterisation: The invention relates to a new use of dabigatran etexilate of formula (I) optionally in the form of the pharmaceutically acceptable salts thereof, and new medicament formulations which may be used for this purpose.... Agent: Boehringer Ingelheim Pharmaceuticals Inc.

20110301203 - Chemical compounds: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline LLC

20110301202 - Spla2 inhibitor conjugate compounds and methods of use: The present application provides a novel set of compounds comprising a sPLA2 inhibitor conjugated to a niacin drug, as well as kits containing these compounds and methods of using the compounds to alter lipid levels and treat various cardiovascular diseases.... Agent:

20110301204 - Administration regime for nitrocatechols: The present invention relates to novel dosage regimens for compounds of formula I: where the substituents are as defined in the specification.... Agent: Bial - Portela & Ca., S.a.

20110301205 - Isoxazole derivatives for use as fungicides: The present invention relates to isoxazole compounds of formula (I) having fungicidal activity, to agricultural compositions comprising them, and to the use of said compounds and compositions in agriculture for the control of microbial pests, particularly fungal pests, on plants.... Agent: Syngenta Crop Protection LLC

20110301206 - Synergistic preservative blends: The present invention is a preservative formulation which includes a combination of at least two (2) compounds having bactericidal and/or fungicidal properties wherein the at least two (2) compounds is selected from the group consisting of methylisothiazolinone/piroctone olamine; caprylyl glycol/dehydroacetic acid; undecanol/dehydroacetic acid and lauryl alcohol/sorbic acid. The invention also... Agent:

20110301207 - Methods and sustained release nicotinic acid compositions for treating hyperlipidemia: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological... Agent:

20110301208 - Viral and fungal inhibitors: Novel classes of viral and fungal inhibitors are disclosed. These compounds are useful in treating, preventing, and/or ameliorating viral infections such as, for example, Hepatitis C Virus, West Nile Virus, Dengue Virus, and Japanese Encephalitis Virus, and fungal infections such as, for example, candidiasis.... Agent: Georgetown University

20110301209 - Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders: Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.... Agent: Tragara Pharmaceuticals, Inc.

20110301210 - Use of pramipexole to treat amyotrophic lateral sclerosis: The present invention is directed to compositions comprising pramipexole and the use of such compositions to treat neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). As shown in FIG. 6B the mean +/−SEM serum 2,3-DHBA levels for the 12 ALS participants decreased significantly after pramipexole treatment.... Agent: University Of Virginia Patent Foundation

20110301211 - Antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent:

20110301212 - Method for treating proliferative disorders associated with protooncogene products: The present invention relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating Bcr-Abl, FLT-3, EGFR, c-Kit, B-raf, and NPM-ALK associated cancers, in a subject in need thereof.... Agent: Synta Pharmaceuticals Corp.

20110301213 - Use of pilocarpine for hypoptyalism treatment: A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves... Agent:

20110301214 - Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol: Disclosed herein is a pharmaceutical composition comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.... Agent: Allegran, Inc.

20110301215 - Inhibitors of plasma kallikrein: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.... Agent: Activesite Phamaceuticals, Inc.

20110301216 - Anticancer and antimicrobial compounds from antarctic extremophilic microorgansims: The present disclosure describes the isolation of extremophilic microorganisms from the Lakes of Schirmacher Oasis located in the East Antarctic Dronning Maud Land. The isolated organisms were characterized and certain pigments produced by these microorganisms were isolated. The present disclosure teaches that the isolated pigments exhibit anticancer and antimicrobial properties... Agent:

20110301217 - Selective glycosidase inhibitors and uses thereof: The application relates to an immoalditol compound for selectively inhibiting glycosidases, a prodrug thereof and a pharmaceutical composition comprising the compound or the prodrug The application also relates to the use of the immoalditol compound for treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency... Agent:

20110301231 - Lipase inhibiting composition: Pharmaceutical compositions that contain a lipase inhibitor having a melting point ≧37° C., a sucrose fatty acid ester wherein the sucrose fatty acid ester is a mono-, di-, tri- or tetra-ester, and optionally one or more pharmaceutically acceptable excipients, are useful for treatment of obesity.... Agent: Hoffmann-la Roche, Inc.

20110301232 - Process of extracting procyanidins by alkaline hydrolysis: A process of extracting procyanidins by alkaline hydrolysis. In particular, a procyanidin-containing material, pomace or residue is treated with an alkali, such as sodium or potassium hydroxide, for a predetermined amount of time and at a predetermined temperature to release procyanidins bound to polysaccharides and/or proteins of the cell wall... Agent: Board Of Trustees Of The University Of Arkansas

20110301233 - Novel polyisoprenylated benzophenone derivatives from garcinia paucinervis: Novel polyisoprenylated benzophenone derivatives isolated from the plant Garcinia paucinervis. Among these new compounds, paucinones A-C (Compounds 1-3) contains an unexpected cyclohexane-spiro-tetrahydrofuran moiety. A 1-methylene-3,3-dimethylcyclohexane group never reported before was found in the structure of paucinone D (Compound 4). Structures of these compounds were elucidated with spectroscopic evidence. The relative... Agent:

20110301234 - Formulations of ladostigil tartrate: The invention relates to a pharmaceutical composition of R(+)-6-(N-methyl,N-ethyl-carbamoyloxy)-N′-propargyl-1-aminoindan ½ tartrate, at least one pharmaceutically acceptable excipient and up to 5% by weight of the composition of water. The composition is typically in a solid oral form which upon administration to a human subject provides a maximum blood plasma concentration... Agent:

20110301235 - Organoselenium compounds and uses thereof: Provided herein are organoselenium compounds and pharmaceutical compositions thereof. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders using the compounds and pharmaceutical compositions provided herein.... Agent: Alquest Therapeutics, Inc.

20110301236 - Hela-c3 apoptosis inducer from garcinia paucinervis: o

20110301237 - Methods and compositions for novel liquid crystal delivery systems: Methods of making a liquid crystal mixture essentially comprised of at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at least one alkali reactant. The resultant mixture includes at least one fatty acid ester or fatty acid, at least one polyhydric solvent, and at... Agent: Copperhead Chemical Company

20110301238 - Seizure related disorders and therapeutic methods thereof: Methods of treating seizure disorders by administration of a therapeutically effective amount of at least one precursor of propionyl-CoA in the absence of a ketogenic diet are provided. The present invention particularly applies to administration of triglyceride oils and preferably, triheptanoin and derivatives thereof.... Agent:

20110301239 - Use of novel lipid mediators to inhibit angiogenesis: The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of... Agent: The Brigham And Women's Hospital, Inc.

20110301240 - Conditioning composition: The present invention is directed to a composition for the conditioning of a dental mineralized surface and/or a dental implant and/or for increasing the hydrophilicity of a dental implant having a metal containing surface. The composition comprises EDTA in a concentration of 21-55% by weight and having a pH of... Agent: Straumann Holding Ag

20110301241 - New halo active aromatic sulfonamide organic compounds and uses therefor: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. This disclosure deals with the use of halo active aromatic sulfonamide organic compounds as odor control and/or... Agent:

20110301242 - Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders: The present invention relates to methods (and pharmaceutical compositions) for treating and/or preventing for obesity associated disorders, particularly related to a deregulation of glucose homeostasis, by administrating Cathepsin S inhibitors. The invention also relates to methods for diagnosing insulin resistance and glucose tolerance by measuring Cathepsin S levels in a... Agent:

20110301243 - Novel method: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an... Agent:

20110301244 - Fast acting naratriptan composition: The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient.... Agent: Emisphere Technologies, Inc.

20110301245 - (r)-2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril formulaitons, andthe use of such formulations in the treatment of conditions mediated by the serotonin transporter: Methods comprising administering compositions comprising therapeutically effective amounts of the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats or prevents at least one condition having serotonin transporter activity in a subject in need thereof, and releases the (R)-isomer of 2-(3,4-dimethoxyphenol)-2-isopropyl-6-azaheptanitril, a derivative... Agent: Agi Therapeutics, PLC

20110301246 - Antifungal compositions for inhibiting growth of wood decay fungi and use thereof: The present invention is related to an antifungal composition for the inhibition of wood decay caused by wood rot fungi. The invention further comprises a method for the inhibition of wood decay with gallates.... Agent: National Taiwan University

20110301247 - Cosmetic product containing film-forming polymer: e

20110301248 - Compositions and methods of delivery of pharmacological agents: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of... Agent:

20110301249 - Stem cell enhanced protein products and uses therof: Methods for producing in-vitro cultured protein products that are enhanced with stem cells are disclosed. In-vitro cultured protein product compositions produced by said methods are also disclosed. The present invention also discloses methods of providing nutrients to an animal by feeding said animal with said in-vitro cultured protein products.... Agent:

20110301250 - Composition for treating dry eye and related methods of manufacture and methods of use: The present invention is directed to a composition for treating dry eye comprising, in one embodiment, carboxymethylcellulose and a polyol. Such compositions have been found to alleviate the symptoms of dry eye and remain in the eye for a long period of time.... Agent:

  
12/01/2011 > 188 patent applications in 139 patent subcategories. patent applications/inventions, industry category

20110294717 - Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers: The present disclosure relates in part to pharmaceutical compositions comprising polymeric nanoparticles having certain glass transition temperatures. Other aspects of the invention include methods of making such nanoparticles.... Agent:

20110294718 - Dipeptoid prodrugs and the use thereof: The present application relates to prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}thio)-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110294719 - Dipeptoid prodrugs and the use thereof: The present application relates to dipeptide-like prodrug derivatives of 2-amino-6-({[2-(4-chlorophenyl)-1,3-oxazol-4-yl]methyl}sulfanyl)-4-(4-{[2,3-dihydroxypropyl]oxy}phenyl)pyridine-3,5-dicarbonitrile, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially of cardiovascular disorders.... Agent: Bayer Schering Pharma

20110294720 - Apratoxin therapeutic agents: mechanism and methods of treatment: The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.... Agent: University Of Florida Research Foundation

20110294721 - Antimicrobial peptides: The present invention relates to a peptide comprising or consisting of a sequence of formula I A-B-C-D-E-F-G-H-I (formula I), wherein A is a peptide consisting of three or four basic amino acid residues; B is a peptide consisting of two to four hydrophobic amino acid residues; C is an amino... Agent: Helmholtz Zentrum M&#xfc Nchen Deutsches Forschungszentrum F&#xfc R Gesundheit Und Umwelt (gmbh)

20110294722 - Antimicrobial peptides: The present invention relates to a peptide comprising or consisting of a sequence of the formula A-B-C-D-E-F (formula I), wherein A is a peptide consisting of three to six basic amino acid residues; B is an amino acid residue or a peptide consisting of two amino acid residues, wherein said... Agent: Helmholtz Zentrum M&#xdc Nchen Deutsches Forschungszentrum F&#xdc R Gesundheit Und Umwlet (gmbh)

20110294723 - Compounds: e

20110294724 - Low hemolytic antimicrobial peptide, pharmaceutical composition and use thereof: Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected... Agent: Rise Technology Co., Ltd.

20110294726 - Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome: The present invention provides for methods of preventing IBS, preventing long term irregular bowel pattern, reducing the likelihood of developing or having IBS, reducing the likelihood of developing or having long term irregular bowel pattern, mitigating IBS, mitigating long term irregular bowel pattern and reducing the likelihood of developing non-ulcer... Agent: Cedars-sinai Medical Center

20110294725 - Use of predissolved pristinamycin-type and polyether ionophore type antimicrobial agents in the production of ethanol: A method of controlling microorganisms such as lactobacilli metabolism in mash in an ethanol production facility includes adding to the mash an effective amount to control such microorganisms of one or more of a substantially water insoluble pristinamycin-type antimicrobial agent, a substantially water insoluble polyether ionophore antimicrobial agent, or both,... Agent: Phibro Animal Health Corporation

20110294728 - Antiviral polypeptides: The invention concerns polypeptides derived from the HIV-1 reverse transcriptase which are capable of inhibiting said polymerase and optionally also capable of inhibiting the HIV-1 integrase 3′ processing activity, and their therapeutic applications.... Agent:

20110294727 - Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective... Agent: Morehouse School Of Medicine

20110294729 - Novel insulin analogues: Insulin analogues wherein the B25 amino acid residue is His or Asn with the proviso that if the B25 amino acid residue is His, then the B27 amino acid residue is Asp or Glu and the A14 amino acid residue is different from Glu, have liver preferential actions.... Agent: Novo Nordisk A/s

20110294730 - Method of treating glaucoma and intraocular hypertension: A safe and effective treatment for glaucoma for mammalian species comprises the steps of applying insulin and/or insulin like growth factors (IGF-1) to an eye. In addition to the insulin, another therapeutic agent may be applied to enhance the activity of the insulin. The therapeutic agent may be a pharmaceutical... Agent:

20110294731 - Skin cream: Preferred embodiments of the invention relate to compositions, including anti-aging cosmeceuticals for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture.... Agent: Invitrx, Inc.

20110294732 - Erythropoletin complementation or replacement: The present invention provides methods and compositions to replace up to 90% of erythropoietin use in the treatment of anemias and hypoxias. The method employs acid and salt forms of inositol-tripyrophosphate (ITPP) isomers to shift the P50 value of hemoglobin, thereby improving the rate and efficiency of oxygenation by blood... Agent: Normoxys, Inc.

20110294733 - Modified human thrombopoietin polypeptide fragment and manufacturing method thereof: The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molecules, preferably fusion proteins comprising immunoglobulin constant regions and modified human TPO, with improved biological... Agent: Hanall Biopharma Co., Ltd.

20110294734 - Pharmaceutical compositions comprising tgf-beta 1 inhibitor peptides: The present invention relates to a complex comprising a TGF-β1 inhibitor peptide and a cyclodextrin or a derivative thereof. A TGF-β1 inhibitor peptide emulsion comprising cetyl PEG/PPG-10/1 dimethicone is also provided. Processes for the preparation of said complex and said TGF-β1 inhibitor peptide emulsion are also described, as well as... Agent: Digna Biotech, S.l.

20110294735 - Mechanism of neuromedin u action and uses thereof: The use of neuromedin U receptor agonists to elevate the levels of GLP-1 and/or PYY in an individual in need of an increase in its levels of GLP-1 and/or PYY is described. Further described is the use of neuromedin U receptor agonists to lower the levels of glucagon in an... Agent: Merck Sharp & Dohme Corp.

20110294736 - Compounds and methods for the treatment of autoimmune and inflammatory disease: The present invention provides a method and composition for the treatment and prevention of an autoimmune disease such a multiple sclerosis which is mediated by autoreactive T cells. The administration of a NOD-1 agonist is shown to mediate an anti-inflammatory immune response. NOD-1 agonists suitable for use in the methods... Agent: The Provost, Fellows And Scholars Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin

20110294737 - Terminally-differentiated anucleate platelet progeny generation: Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic... Agent:

20110294738 - Pthr1 receptor compounds: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the... Agent:

20110294739 - Use of the engrailed homeodomain protein as anxiolytic: The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.... Agent:

20110294740 - Treatment of amyloidoses using myelin basic protein and fragments thereof: In its various embodiments, the invention provides myelin basic proteins and fragments of that interfere with the fibril lization of peptides implicated in the amyloidoses, especially the amyloid-beta peptide associated with Alzheimer's disease (“AD”) and cerebral amyloid angiopathy (“CAA”). Some embodiments provide methods of identifying additional interfering fragments. Others provide... Agent: The Research Foundation Of State University Of New York

20110294741 - Use of compounds in the treatment of tau-induced cytotoxicities: The present invention relates to derivatives of L-Tyrosyl-L-Arginine and the use of said derivatives in the prevention and/or treatment of a tau-induced cytotoxicity.... Agent: Bioalvo-servicos, Investigacao E Desenvolvimento Em Biotecnologia S.a.

20110294742 - Degradable clostridial toxins: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a... Agent: Allergan, Inc.

20110294743 - Metastasis-specific peptides and their diagnostic and therapeutic applications: The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.... Agent: Universita Degli Studi Di Torino

20110294744 - Cyclosporin emulsions: Disclosed herein is a composition comprising cyclosporin A at a concentration between about 0.001% (w/v) and about 1.0% (w/v), a plant oil at a concentration between about 0.01% (w/v) and about 10% (w/v), and macrogol 15 hydroxystearate at a concentration between about 0.01% (w/v) and about 10% (w/v).... Agent: Allergan, Inc.

20110294745 - Solutions of lipophilic substances, especially medicinal solutions: The present invention relates to a solution containing at least one water-miscible biocompatible solvent and a lipophilic substance dissolved therein, wherein upon contact with aqueous body fluid the dissolved lipophilic substance is precipitated out of the solution in the form of nanoparticles and a nanosuspension is formed.... Agent: Universit&#xc4 T Regensburg

20110294746 - Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules: The present invention refers to a microemulsion formulation suitable for preventing assembly of amphiphilic drug molecules which may cause hypersensitivity reactions and other unwanted side effects.... Agent: Azad Pharma Ag

20110294747 - Pegylated mutated clostridium botulinum toxin: e

20110294748 - Insulin-like growth factor 1 receptor binding peptides: The present invention relates to insulin-like growth factor 1 receptor binding peptides, polynucleotides encoding them, and methods of making and using the foregoing.... Agent:

20110294749 - Diaminopyrimidinecarboxamide derivative: e

20110294750 - Surface sterilisation by misting with a bioflavanoid solution: There is described a method of sterilizing surfaces using flavonoids, for example mixtures containing inter alia naringin and neohesperidin, by misting.... Agent: Citrox Biosciences Limited

20110294751 - High dosage doramectin formulation: Veterinary compositions which provide a high-dose of doramectin or a high-dose veterinary combination composition which comprises doramectin and one or more other antiparasitic agents is disclosed. The compositions provide both antiparasitic efficacy and a significantly reduced withhold time.... Agent: Pfizer Inc.

20110294752 - Triterpene compositions and methods for use thereof: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to... Agent: Research Development Foundation

20110294753 - Means and methods for counteracting muscle disorders: The invention provides means and methods for alleviating one or more symptom(s) of Duchenne Muscular Dystrophy and/or Becker Muscular Dystrophy. Therapies using compounds for providing patients with functional muscle proteins are combined with at least one adjunct compound for reducing inflammation, preferably for reducing muscle tissue inflammation, and/or at least... Agent: Academisch Ziekenhuis Leiden

20110294871 - Lipids, lipid complexes and use thereof: e

20110294865 - Methods of detecting a fragment of neurosecretory protein vgf for diagnosing alzheimer's disease: The present invention provides a neurosecretory protein VGF peptide useful in qualifying Alzheimer's disease status in a patient. In particular, this peptide and modified forms thereof may be used to classify a subject sample as Alzheimer's disease or non-Alzheimer's disease. The peptide biomarker can be detected by SELDI mass spectrometry.... Agent: Vermillion, Inc.

20110294868 - Modulation of transthyretin expression: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.... Agent:

20110294866 - Pharmaceutical composition for treating dementia comprising shrna inhibiting s100a9 expression: Disclosed is a composition for treating dementia including shRNA to inhibit expression of S100a9. More particularly, the present disclosure describes a composition for prevention or treatment of dementia which includes shRNA having a nucleotide sequence defined by SEQ. ID No. 1 or 2 or a mixture thereof wherein the nucleotide... Agent: Snu R&db Foundation

20110294869 - Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference: Disclosed herein are compositions and methods for generating ribo-nucleic neutral (RNN) or deoxyribo-nucleic-neutral (DNN) polynucleotides with reduced anionic charge, for improved intracellular delivery. Also disclosed herein are methods of using RNN and DNN compositions.... Agent: Traversa Therapeutics, Inc.

20110294867 - Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions: The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short... Agent: Universite Joseph Fourier

20110294870 - Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with... Agent: Opko Curna, LLC

20110294874 - Diagnosis and therapy of organ dysfunction using sphinganine-1-phosphate: The invention relates to the treatment and diagnosis of organ dysfunction caused by ischemia reperfusion injury. In particular, the invention relates to sphinganine-1-phosphate, a sphingolipid metabolite, and its use in the diagnosing, preventing, and/or treating ischemia reperfusion-associated disorders, including, without limitation, disorders of the kidney, liver, lung, brain, and heart.... Agent: The Trustees Of Columbia University In The City Of New York

20110294873 - Gene transfer vectors comprising at least one isolated dna molecule having insulator or boundary properties and methods to identify the same: The present invention relates to gene transfer vectors and in particular expression vectors which comprise at least one isolated DNA molecule having insulator and or boundary properties which limits the effects of a regulatory sequence upon another regulatory or coding sequence disposed upon the other side of said at least... Agent: Universit&#xc9 De Lausanne

20110294872 - High-affinity nucleic acid aptamers against sclerostin protein: Described are nucleic acid aptamers that are able to bind to and inhibit the function of sclerostin, which is an important negative regulator of bone growth. The aptamers have application as therapeutics for diseases of bone including osteoporosis, osteopenia, osteoarthritis and other osteoporosis-related conditions and complications.... Agent: The University Of Hong Kong

20110294754 - Novel pharmaceutical compounds: Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders.... Agent:

20110294755 - Binding of galectin-3 by low molecular weight pectin: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum... Agent:

20110294756 - Gamma secretase modulators: In its many embodiments, the present invention provides a novel class of heterocyclic compounds of Group A or Group, as defined herein, as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such... Agent:

20110294757 - Polar lipid mixtures, their preparation and uses: Disclosed herein are polar lipid mixtures, comprising glycerophospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidyl-inositol (PI), and sphingolipids such as sphyngomyelin (SM). Most importantly, the ratio of phospholipids in said mixture is comparable to that of HMF, and is represented by SM>PC>PE>PS>PI or SM=PC>PE>PS>PI. Processes for the... Agent:

20110294758 - Novel activators of glucokinase: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the... Agent: Metabasis Therapeutics, Inc.

20110294759 - Once daily formulations of tetracyclines: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.... Agent: Supernus Pharmaceuticals, Inc.

20110294760 - Compositions and methods for preventing sternal wound infections: The invention generally relates to compositions and methods for preventing sternal wound infections, such as mediastinitis. In certain embodiments, the invention provides an antimicrobial composition including at least one bioresorbable polymer, such as a tyrosine-derived polyesteramide, and at least one antimicrobial agent, in which the composition is adapted to be... Agent: Tyrx Pharma, Inc.

20110294761 - Stem cell cultures: The present invention relates compounds for stabilizing cells and methods of their use.... Agent: The Scripps Research Institute

20110294762 - Glyceryl and glycol acid compounds: A composition comprising a glyceryl salicylate compound and/or a glycol salicylate compound. The compositions can be used to reduce the amount of moisture evaporated from skin, protect the skin from UV light, and treat aged or damaged skin.... Agent: Mary Kay Inc.

20110294763 - Transdermal delivery of dicolfenac, carbamazepine and benzydamine: The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature.... Agent:

20110294764 - 2-methylene-19,26-nor-(20s)-1alpha-hydroxyvitamin d3: Compounds of formula I are provided where X1 and X2 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.... Agent:

20110294765 - Procedure for obtaining an aqueous dispersion of alcohols and acids from jojoba oil, processes for obtaining self-emulsified jojoba oil, aqueous dispersions and emulsions of jojoba oil in the same and pharmaceutical or cosmetic compositions comprising the: Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with... Agent: G.s.p. Emprendimientos Agropecuarios Sociedad Anonima And Universidad Nacional De Cordoba

20110294766 - 16 alpha, 17 alpha-acetal glucocorticosteroidal derivatives and their use: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Astrazeneca Ab

20110294767 - Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions: Provided herein are methods of utilizing bile acid transport inhibitors and/or enteroendocrine peptide enhancing agents for the treatment of obesity, diabetes, and inflammatory gastrointestinal conditions.... Agent: Satiogen Pharmaceuticals, Inc.

20110294768 - Ophthalmic suspension for ocular use: A gatifloxacin and prednisolone topical ophthalmic pharmaceutical compositions for prevention and treatment of ophthalmic bacterial infections and inflammatory conditions associated with pre-surgical and/or post surgical ocular surgeries.... Agent: Allergan, Inc.

20110294769 - Nitrooxy derivatives of glucocorticoids: The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability.... Agent: Nicox S.a.

20110294770 - Method for producing pharmaceutical drug particles of small particle size: Pharmaceutical drug particles of small particle size are produced by combining a solvent-non-solvent precipitate with an in-situ spray drying process. A pharmaceutical drug is dispersed in a water-miscible solvent, in particular ethanol, and heated in an infeed line under pressure to above the boiling point of the solvent until the... Agent: Mjr Pharmjet Gmbh

20110294771 - Treatment of muscular dystrophy: The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.... Agent: Corcept Therapeutics, Inc.

20110294772 - Use of cyclosquaramide compounds as anti-tumour agents: Use of squaramide-based macrocylic compounds as kinase inhibitor agents and as anti-tumour agents. More specifically, said compounds are used to treat diseases such as cancer, diabetes, neurodegenerative diseases, HIV replication, etc. Furthermore, the present invention likewise relates to pharmaceutical compositions that contain said compounds... Agent:

20110294773 - Cosmetic composition and hair wash: e

20110294774 - Identification and application of antibiotic synergy: The present invention provides a pharmaceutical composition useful for treating bacterial infections in humans and animals which comprises administering to a human or animal in need thereof, an antibacterially effective combination of a β-lactam antibiotic and an inhibitor of any bacterial peptidoglycan biosynthesis enzyme, especially GlmU, GlmU, MurA, MurB, MurC,... Agent: Trius Therapeutics

20110294775 - Novel compounds: Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:... Agent: Boehringer Ingelheim International Gmbh

20110294777 - Beta-lactamase inhibitors: Substituted bicyclic beta-lactams of Formula I: (I), are β-lactamase inhibitors, wherein a, X, R1 and R2 are defined herein. The compounds and pharmaceutically acceptable salts thereof are useful in the treatment of bacterial infections in combination with β-lactam antibiotics. In particular, the compounds can be employed with a β-lactam antibiotics... Agent: Merck Sharp & Dohme Corp.

20110294778 - Hepatitis c inhibitor compounds: b

20110294779 - Novel imidazopyridines: wherein R1, R2, R3, R4, R5 and A are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used for the treatment of various diseases, including central nervous system disorders such as Alzheimer's disease,... Agent:

20110294776 - Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases: This invention relates to novel compounds of formula (I). Formula (I) in which the variable groups are as defined in the specification and claims, to pharmaceutical compositions containing them, and to a method of treatment using them for treatment of cancer.... Agent: Bayer Healthcare Ag

20110294781 - Pyrazolo-pyrimidine compounds: The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.... Agent: Ajinomoto Co., Inc.

20110294780 - Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-a modulators: methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to... Agent:

20110294783 - Insecticidal compositions having improved effect: The present invention concerns boosting the activity of crop protection materials comprising inhibitors of fatty acid biosynthesis (for example phenyl-substituted cyclic ketoenols) through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them,... Agent: Bayer Cropscience Ag

20110294782 - Small molecule pak inhibitors: The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering small molecule p21-activated kinase (PAK) inhibitors to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides specific small molecule PAK inhibitors... Agent: Massachusetts Institute Of Technology

20110294784 - Gamma secretase modulators: This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (Chemical formula should be inserted here as it appears on abstract in paper form). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula... Agent:

20110294785 - Influenza a virus inhibition: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being... Agent: The Trustees Of The University Of Pennsylvania

20110294786 - Substituted bicyclic pyrimidone derivatives: Wherein Y, Z, R1, R2, R3, R4, R5, R6, R7, n, m, and o are as described herein. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused... Agent: Sanofi-aventis

20110294787 - Substituted thiomorpholine derivatives: The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.... Agent: H. Lundbeck A/s

20110294788 - Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof as hif activators: The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.... Agent: Sanofi

20110294790 - Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents: Bicyclic pyrazole and isoxazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases mediated by HSP90 protein, like cancer... Agent: Nerviano Medical Sciences S.r.l.

20110294789 - Compounds for rho kinase inhibition and for improving learning and memory: The present invention provides a compound of Formula (I) and methods for improving memory, inhibiting rho kinase 1 or 2, inhibiting PIM kinase, or inhibiting IRAK1 kinase in a subject by administering a therapeutically effective amount of the compound.... Agent: Amnestix, Inc.

20110294791 - Pirenzepine as an agent in cancer treatment: The present invention generally relates to the neuroprotective activity of condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine. These compounds are suitable as co-medicaments for the prevention and/or treatment of drug-induced neurotoxic effects in general and neurotoxic side effects... Agent: Proteosys Ag

20110294792 - Purine derivatives as kinase inhibitors: The present invention provides kinase inhibitors of Formula I.... Agent: Eli Lilly And Company

20110294793 - Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors: The present invention provides compound of Formula (I): or a stereoisomer, tautomer, salt or solvate thereof, wherein the variables are defined herein. The compounds of formula (I) are inhibitors of Bcl-2 family antiapoptotic proteins, compositions containing the compounds and methods of treating diseases using the compounds.... Agent: Bristol-myers Squibb Company

20110294794 - Treatment of proteinopathies using a farnesyl transferase inhibitor: Methods and pharmaceutical compositions comprising a low dose of a farnesyl transferase inhibitor useful in the treatment of proteinopathies are provided. These low doses are below the doses used in oncological treatments for which these compounds were initially designed. The treatment includes administering to a subject in need thereof a... Agent: Link Medicine Corporation

20110294795 - Methods of synthesis and/or purification of diaminophenothiazinium compounds: which are characterised by: a purity of greater than 98%; less than 1% Azure B as impurity; less than 0.15% Azure A as impurity; less than 0.15% Azure C as impurity; and less than 0.05% Methylene Violet Bernthsen (MVB) as impurity. Examples include methylthioninium chloride (MTC), also known as Methylene... Agent: Wista Laboratories Ltd.

20110294796 - Benzotriazine inhibitors of kinases: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.... Agent: Targegen, Inc.

20110294797 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Choongwae Pharma Corporation

20110294798 - Il-12 modulatory compounds: The invention relates to cyclic hydrazone compounds, compositions including the cyclic hydrazone compounds and methods of using and methods of making thereof. The compounds (and compositions) are useful, inter alia, in modulating IL-12 production and processes mediated by IL-12.... Agent: Synta Pharmaceuticals Corp.

20110294799 - Organic compounds: e

20110294800 - Hypoglycemic dihydropyridones: The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood... Agent: The Trustees Of Columbia University In The City Of New York

20110294801 - Macrocyclics pyrimidines as aurora kinase inhibitors: Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and... Agent: Merck Patent Gmbh

20110294804 - Novel bicyclic heterocyclic compound: The invention provides a compound for the treatment or prophylaxis of pathology involving SNS, specifically diseases such as neuropathic pain, nociceptive pain, dysuria, multiple sclerosis and the like. The compound is represented by formula (1) or a pharmaceutically acceptable salt thereof wherein R1 is a hydrogen atom or the like,... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20110294802 - Pharmaceutically acceptable salts of methyl (3-{ [[3-(6- amino- 2-butoxy-8-oxo-7, 8-dihydro-9h-purin-9-yl) propyl] (3- morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy: The present invention concerns hydrochloric acid, hydrobromic acid and maleic acid salts of methyl (3-{[[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl](3-morpholin-4-ylpropyl)amino]methyl}phenyl)acetate, compositions comprising them and their use in therapy.... Agent:

20110294803 - Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders: Methods for treating CNS disorders such as schizophrenia, psychosis and cognitive disorders using specific inhibitors of phosphatidylinositol-3-kinase p110 delta (PIK3CD) expression and/or activity are described. Methods of determining risk of CNS disorders and methods of determining treatment response are also described. An integrative systems biology approach to identify a signaling... Agent:

20110294805 - Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators and methods of use thereof: wherein A1, A2, B, R1, R2, R4, R5, R6 and Z are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease,... Agent: Amgen Inc.

20110294806 - Azaindole derivatives as kinase inhibitors: This invention relates to compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.... Agent: Ariad Pharmaceuticals, Inc.

20110294807 - Compounds for the prevention and treatment of cardiovascular disease: Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula... Agent:

20110294808 - Indazole compounds as ccr1 receptor antagonists: Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these... Agent: Boehringer Ingelheim International Gmbh

20110294809 - Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betahsd1: The invention relates to tropane urea derivatives of general formula (I) and to the application thereof as modulators of the activity of 11β-hydroxysteroid dehydrogenose type 1 (11βHSD1).... Agent: Sanofi-aventis

20110294811 - Abt-263 crystalline forms: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.... Agent: Abbott Laboratories

20110294810 - Substituted (pyridyl)-azinylamine derivatives as plant protection agents: The present invention relates (pyridyl)-azinylamino derivatives of formula (I) wherein Q1 and p, Ra to Rc, X, Y, Z, L2 and Q2 represent various substituents, their process of preparation, preparation intermediate compounds, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control... Agent:

20110294812 - P38 map kinase inhibitors: or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in... Agent:

20110294813 - Oxazolidinone derivative having inhibitory activity on 11beta-hydroxysteroid dehydrogenase type 1:

20110294814 - Compounds for treating proliferative disorders: Disclosed are compounds of Formula (I) and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a... Agent: Synta Pharmaceuticals Corp.

20110294815 - Prostacyclin analogs: This invention relates to novel prostacyclin analogs and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel prostacyclin analogs that are derivatives of treprostinil. This invention also provides compositions comprising a compound of this invention and a carrier and the use disclosed compounds and compositions in methods of... Agent:

20110294816 - Pyrrolotriazine kinase inhibitors: i

20110294817 - N-[piperazinyl hetaryl]arylsufonamide compounds with affinity for the dopamine d3 receptor: The invention related to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Ra which is/are selected, independently of each other, from halogen, CN, NO2,... Agent:

20110294818 - 1h-quinazoline-2,4-diones: e

20110294819 - Hepatitis c virus inhibitors: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.... Agent: Bristol-myers Squibb Company

20110294820 - N-oxides of n-phenyl-2-pyrimidine-amine derivatives: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment... Agent:

20110294821 - 5-ht1a receptor subtype agonist: e

20110294822 - Substituted phenylpiperazinyl aralkylalcohol derivatives, pharmaceutical compositions containing such derivatives and uses thereof: wherein C1 and C2 represent chiral carbon atoms, and the compound is one of the six isomers: (1RS, 2SR), (1RS, 2RS), (1R, 2S), (1S, 2S), (1R, 2R) or (1S, 2R); and R, R1, R2, R3 and Ar are as defined in the specification. The derivative is non-opioid analgesic, has good... Agent: Nhwa Pharma. Corporation

20110294823 - Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperzaine compounds: Tetrahydroindolone and aryl piperazine derivatives for use in treating post-traumatic stress disorder and acute stress disorder.... Agent:

20110294824 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders,... Agent: Merck Patentgesellschaft

20110294825 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders,... Agent: Merck Patentgesellschaft

20110294827 - Iap binding compounds: IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kd of less that 0.1 micromolar. Methods of using... Agent: Tetralogic Pharmaceuticals Corporation

20110294826 - Pyrrolo[2,3-d]pyrimidine compounds: Described herein are pyrrolo[2,3-d]pyrimidine compounds, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing these compounds, and methods for their preparation.... Agent: Pfizer Inc.

20110294829 - Fungicide hydroximoyl-heterocycles derivatives: wherein T represents a substituted or non-substituted heterocyclyl group, Q represents a carbo or heterocyclic group, A represent a carbo or heterocyclic group or a carbo or hetero-polycylic group, and L1 represents various linking groups, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents,... Agent:

20110294830 - Nitrogen-containing compounds and harmful organism control agents: The present invention provides a nitrogen-containing compound represented by formula (I1) (in formula (I1), R0 represents a nitro group or the like, Z represents an optionally substituted aryl group or the like, R3 represents a hydrogen atom or the like, Y represents a nitro group or the like, n represents... Agent: Nippon Soda Co., Ltd.

20110294828 - Process for preparing a polymorph of the choline salt of a pyrimidin-5-yl acetic acid derivative: Provided is a process for preparing a choline salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid. The process of the invention is useful for preparing the salt in purer forms of the salt. Also disclosed is a more pure form of the of choline salt of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl]acetic acid.... Agent: Boehringer Ingelheim International Gmbh

20110294831 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the... Agent: S*bio Pte Ltd.

20110294832 - Fused ring compound and use thereof: Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or... Agent: Takeda Pharmaceutical Company Limited

20110294834 - Alkyl-substituted pyrazolopyrimidines: The invention relates to novel alkyl-substituted pyrazolopyrimidines, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory.... Agent:

20110294833 - Methods for healthy aging: Genome-wide association studies have been used to elucidate genes and/or pathways related to diseases; however, this methodology has yet to be used to understand the phenotype of healthy aging and/or healthspan in humans.... Agent: Scripps Health

20110294836 - Aryl gpr119 agonists and uses thereof: Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.... Agent: Metabolex, Inc.

20110294835 - Muscarinic agonists as cognitive enhancers: A method of treating a mental condition in a subject in need thereof, comprising: administering to a subject in need thereof an effective amount of compound CDD-102A.... Agent: University Of Toledo

20110294837 - Aurora kinase modulators and methods of use: wherein A1-6, L1, R1, R4-6 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing... Agent: Amgen Inc.

20110294838 - Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine: e

20110294839 - Novel polymorphs of lopinavir: The present invention provides a novel cyclohexane solvate form of lopinavir, and a process for its preparation thereof. The present invention also provides a novel desolvated crystalline form of lopinavir, process for its preparation and to pharmaceutical composition containing it. Thus, for example, lopinavir cyclohexane solvate was heated at 100°... Agent: Hetero Research Foundation

20110294840 - Hydrazide compound and use of the same in pest control: There is provided a hydrazide compound having a controlling effect on pests represented by the formula (1): wherein, G is a 5-membered heterocyclic group, M is an oxygen atom or a sulfur atom, Q1, Q2, Q3 and Q4 is independently a nitrogen atom, etc., m is an integer of 0... Agent:

20110294841 - Novel statin pharmaceutical compositions and related methods of treatment: The invention provides novel omega-3 oil formulations of one or more statins. These formulations are readily bioavailable. Notably, because the formulations of the invention contain an omega-3 oils as the major ingredient, they not only provide an antihypercholesterolemic effect due to the statin active ingredient, they also provide recommended daily... Agent:

20110294842 - Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain: This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R1, R2a, R2b, R2c, R2d and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for... Agent: Xenon Pharmaceuticals Inc.

20110294843 - Administration scheme of polar opioid metabolites for post-operative pain management: Administration scheme of an analgesically active polar metabolite of an opioid or the salt thereof for the manufacture of a medicament for the treatment of pain after medical operation, whereas the medicament is administered at least once before the end of the medical operation.... Agent: Paion Uk Limited

20110294844 - 9-aminonoscapine and its use in treating cancers, including drug-resistant cancers: 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing... Agent: Emory University

20110294845 - Parenteral formulations: This invention provides CCI-779 cosolvent concentrates which are useful in preparing a parenteral formulation of rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779) following admixture with a diluent.... Agent: Wyeth LLC

20110294846 - Indole derivatives as anticancer agents: The present invention provides compounds of formula (I), their use for the treatment of cancer as well as pharmaceutical compositions comprising said compounds of formula (I).... Agent: Janssen Pharmaceutica Nv A Corporation

20110294847 - Novel polymorphs of azabicyclohexane: The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph... Agent:

20110294849 - Aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase: The present invention relates to anhydrous and hydrated forms of Compound 1, which qre useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110294850 - Indoline derivatives: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl... Agent: Kyoto University

20110294848 - Small molecule inhibitors of botulinum neurotoxins: The invention provides potent quinolinol-based BoNT/A small-molecule inhibitors of botulinum neurotoxins, in particular of Clostridium botulinum serotype A neurotoxins. The invention also provides methods of using these small-molecule inhibitors to inhibit infections by Clostridium botulinum, as well as, methods of preventing infections by Clostridium botulinum through materials that may be... Agent:

20110294851 - Amidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, where R1-3, R5, R7, a, b, Q, X, X′, X″, Y, Z, and Ar are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also relates to pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of... Agent: Theravance, Inc.

20110294852 - Pharmaceutical formulation comprising metformin and repaglinide: The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or... Agent: Novo Nordisk A/s

20110294853 - Bis aromatic compounds for use in the treatment of inflammation: There is provided compounds of formula (I), wherein ring A, D1, D2a, D2b, D3, Y, Y1, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and... Agent:

20110294854 - Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators: e

20110294855 - Active compound combinations: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) the compound 3-(difluoromethyl)-N-[2-(1,1,2,3,3,3-hexafluoro propoxy)phenyl]-1-methyl-1H-pyrazole-4-carboxamide of formula (I) and/or the compound 3-(di fluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1H-pyrazole-4-carboxamide of formula (II) and (B) at least one azolylmethyloxirane of formula (III). Moreover, the invention relates to a method for curatively... Agent: Bayer Cropscience Ag

20110294857 - Inhibitor of casein kinase 1delta and casein kinase 1epsilon: [wherein, in the formula (1), each of R1 and R2 independently represents any one of a substituted or unsubstituted 6-membered or 5-membered heterocyclic group optionally having a condensed ring, a substituted or unsubstituted aromatic hydrocarbon group optionally having a condensed ring, and a substituted or unsubstituted aromatic hydrocarbon lower alkyl... Agent: Pharmadesign, Inc.

20110294856 - Novel oxadiazole derivatives and their medical use: This invention relates to novel oxadiazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central... Agent:

20110294858 - Substituted 6-methylnicotinamides as mglur5 positive allosteric modulators: In one aspect, the invention relates to substituted 6-methylnicotinamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated... Agent:

20110294859 - Substituted pyridoxine-lactam carboxylate salts: The present invention provides salt adducts comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, methods of their preparation, and pharmaceutical compositions and medicaments comprising them. Salt adducts of the invention and... Agent: Alcobra Ltd.

20110294860 - Aqueous oral preparation of stable amlodipine: The invention provides a stable and rapidly disintegrable aqueous oral preparation (liquid or jelly preparation) of amlodipine. The liquid preparation comprises an anionic surfactant having a sulfuric acid group or a sulfonic acid group as a stabilizer in an aqueous solution of amlodipine, at pH 5-7, while the jelly preparation... Agent: Medrx Co., Ltd.

20110294861 - Method of treatment of hereditary hemochromatosis: e

20110294862 - Treatment or prevention of hypotension and shock: A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering... Agent: Orion Corporation

20110294863 - Fungicide n-cycloalkyl-n-bicyclimethylene-carboxamide derivatives: The present invention relates N-cycloalkyl-N-bicyclicmethylene-carboxamide, thiocarboxamide or N-substituted carboximidamide derivatives of formula (I) wherein A represents a carbo-linked, 5-membered heterocyclyl group, T represents O or S, Z1 represents a C3-C7-cycloalkyl group, X represents N or a CZ7 and Y1, Y2, Z2, Z3, L1 and L2 represent various substituents, their process... Agent:

20110294864 - Aqueous coacervate compositions suitable for making powders and water-soluble formulations of biologically-active agents: e

20110294875 - 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.... Agent:

20110294876 - Cyclohexyl carbamate compounds as anti-ageing actives: The invention further relates to corresponding methods and to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) and one or more further anti-ageing actives. The invention further relates to compounds of formula (I) as a drug, their use for the preparation of... Agent: Symrise Ag

20110294877 - Transition metal complexes of bis[thiohydrazide amide] compounds: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I), or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. In one embodiment,... Agent: Synta Pharmaceutical Corp.

20110294878 - Inhibitors of dimethylarginine dimethylaminohydrolase: The invention relates to an inhibitor of dimethylarginine dimethylaminohydrolase (DDAH) of general structural formula (I), wherein B is a branched or unbranched, substituted or non-substituted, saturated or unsaturated hydrocarbon chain having a chain length of 1 to 6 and/or a substituted or non-substituted aromatic system having a ring size of... Agent: Christian-albrechts-universitaet Zu Kiel

20110294879 - Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and/or autism, comprising administering a prodrug of acamprosate to a subject suffering therefrom, wherein, in certain embodiments, the acamprosate prodrugs comprise compounds of Formula (I).... Agent: Xenoport, Inc.

20110294880 - Pharmaceutical composition containing prostaglandin: An object of the present invention is to provide a stable aqueous pharmaceutical composition which suppresses degradation of prostaglandin F2α in a preparation containing prostaglandin F2α. The object was attained by formulating a prostaglandin F2α derivative into an oil-in-water emulsion together with an oil, for example, medium chain fatty acid... Agent: Senju Pharmaceutical Co., Ltd.

20110294881 - Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators: A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in... Agent: Edusa Pharmaceuticals, Inc.

20110294882 - Novel derivatives of 3,3-diphenylpropylamines: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine,... Agent: Ucb Pharma Gmbh

20110294883 - Alpha-derivatives of cis-monounsaturated fatty acids intended for use as a drug: Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines. The present invention refers to pharmaceutically acceptable compounds of Formula I, their salts and derivatives, where (a) and (b) can take any value between 0 and 14, (X) can be substituted by any atom or group of atoms with an atomic/molecular... Agent: Universitat De Les Illes Balears

20110294884 - Bipolar trans carotenoid salts and their uses: The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.... Agent: Diffusion Pharmaceuticals LLC

20110294885 - Controlled-release pregabalin compositions: An orally-administrable controlled-release formulation, including pregabalin or a pharmaceutically acceptable salt of pregabalin and polycarbophil, as a controlled-release agent.... Agent: Sanovel Iiac Sanayi Ve Ticaret Anonim Sirketi

20110294887 - Controlled-release solution formulations of pregabalin: A controlled-release oral solution formulation, which gels in the stomach, includes pregabalin or a pharmaceutically acceptable salt of pregabalin and a gelling agent.... Agent: Sanovell Illac Sanayi Ve Ticaret Anonim Sirketi

20110294886 - Controlled-release tablet formulations of pregabalin: A controlled-release tablet formulation which gels in the stomach, including pregabalin or a pharmaceutically acceptable salt thereof, and a complex of sodium alginate and calcium chloride, or calcium alginate, or a properly-proportioned mixture thereof as a controlled-release agent.... Agent: Sanovell Llac Sanayi Ve Ticaret Anonim Sirketi

20110294888 - Use of salts of sulfur-containing compounds for controlling parasites: The invention relates to a method of controlling nematodes with salts of sulphur-containing compounds.... Agent:

20110294889 - Infusion and injection solution of levodopa: An infusion or injection solution of Levodopa containing at least 10 mg/mL of Levodopa, or at least 5 mg/mL of Levodopa together with at least 0.5 mg/mL of at least one inhibitor of a Levodopa-metabolising enzyme is disclosed. The solution further contains a buffer, a physiologically acceptable sugar, such as... Agent:

20110294890 - Neramexane for the treatment or prevention of inner ear disorders: The present invention relates to a method of treatment or prevention of an inner ear disorder in a female comprising administering a therapeutically effective amount of neramexane or a pharmaceutically acceptable salt thereof to a female.... Agent: Merz Pharma Gmbh & Co. Kgaa

20110294891 - Methods and compositions for treating opthalmic conditions with retinol derivatives: Compounds that cause reversible night blindness may be used to treat ophthalmic conditions associated with the overproduction of waste products that accumulate during the course of the visual cycle. We describe methods and compositions using such compounds and their derivatives to treat, for example, the macular degenerations and dystrophies or... Agent: Revision Therapeutics, Inc.

20110294892 - Use of histone deacetylase inhibitors for the care of philadephia-negative myeloproliferative syndromes: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for... Agent:

20110294893 - Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents: The present invention provides cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compounds, which may be substituted in the 1-position with amino, amido, ether or ester groups, e.g., a 1-OH cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compound. The cyclopentane heptanoic acid, 2-(cycloalkyl or arylalkyl) compounds of the present invention are potent ocular... Agent: Allergan, Inc.

20110294894 - Pharmaceutical composition for the treatment of solar urticaria: The present invention refers to a local anesthetic, preferably selected from the group of aminoamide local anesthetics, in particular lidocaine or prilocaine, for use in the treatment or prevention of physical urticaria, in particular solar urticaria. The present invention further refers to a pharmaceutical composition, e.g. a cream, comprising such... Agent:

20110294895 - Bis(thio-hydrazide amide) formulation: e

20110294896 - Topical treatment with dapsone in g6pd-deficient patients: The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a... Agent:

20110294897 - Treating xerophthalmia with compounds increasing meibomian gland secretion: Methods for the treatment of patients suffering from dry eyes, by using adrenergic beta-receptor agonists, particularly salbutamol and in particular the optically pure or substantially pure R-enantiomer thereof. The embodiments disclosed herein include methods of increasing the Meibomian lipid secretion and thereby reducing or eliminating xerophthalmia symptoms by the administration... Agent: Bridge Pharma, Inc.

20110294898 - Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride: A hitherto unknown crystalline form of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.... Agent: Gruenenthal Gmbh

20110294899 - Defoamer composition comprising alkoxylated 2-propylheptanol: The present invention relates to defoaming compositions comprising compounds having the formula C5H11CH(CH2CH2CH3)CH2O(CH2CH(X)O)nH (I) where X=(CH2)aCH3 where a=0 or 1 and where n=0.5-5; and one or more hydrotropes selected from the group consisting of branched or linear C4-C10 alkyl glycosides and optionally one or more anionic hydrotrope selected from the... Agent: Akzo Nobel N.v.

20110294900 - Self emulsifying drug delivery system for a curcuminoid based composition: The present invention discloses a pharmaceutical composition in the form of self nano emulsifying drug delivery formulation comprising curcuminoids. The pharmaceutical composition of the present invention shows an enhanced drug loading ability, better stability and an improved bioavailability. The composition of the present invention comprises of a pharmaceutically effective amount... Agent: Arbro Pharmaceuticals Ltd.

20110294901 - Finely pulverized pharmaceutical composition: An objective of the present invention is to provide a composition that has improved oral absorption and comprises a slightly soluble drug, and to provide a process for producing the same. According to the present invention, there is provided a finely pulverized composition comprising a slightly soluble drug such as... Agent:

20110294902 - Pharmaceutical compositions providing enhanced drug concentrations: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.... Agent:

20110294903 - Large particle size crystallised maltitol powder, method for preparing same and applications thereof, particularly in chocolate production: A crystallized maltitol powder including a maltitol content greater than 99.5% by weight, characterized by a particle-size distribution by volume, determined by laser granulometry, having less than 20% particles less than 200 μm in size, less than 6% particles less than 100 μm in size, less than 2% particles less... Agent: Roquette Freres

20110294904 - Dry granulation binders, products, and use thereof: A method for the preparation of microcrystalline cellulose containing tablets by roller compaction followed by tabletting is disclosed. A tablet formulation is converted to a dry granulate by roller compaction, and the dry granulate lubricated dry granulate and compacted to a tablet. The tablet formulation comprises at least one active,... Agent: Fmc Corporation

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140807: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 4.13939 seconds

PATENT INFO